

Prescription and Over-the-Counter Drug Product List

46TH EDITION

Cumulative Supplement Number 03 : March 2026

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

| | | | | | | | | |
|-----|----|-------|-------|---------|-----|--------------|-----|------|
| >A> | AB | APPCO | 333MG | A218984 | 001 | Mar 16, 2026 | Mar | NEWA |
|-----|----|-------|-------|---------|-----|--------------|-----|------|

ACARBOSE

TABLET;ORAL

ACARBOSE

| | | | | | | | | |
|-----|--|--------------------|-------|---------|-----|--------------|-----|------|
| >D> | | @ DASH PHARMS | 25MG | A091053 | 001 | Jan 06, 2011 | Mar | CAHN |
| >D> | | @ | 50MG | A091053 | 002 | Jan 06, 2011 | Mar | CAHN |
| >D> | | @ | 100MG | A091053 | 003 | Jan 06, 2011 | Mar | CAHN |
| >A> | | @ NATCO PHARMA USA | 25MG | A091053 | 001 | Jan 06, 2011 | Mar | CAHN |
| >A> | | @ | 50MG | A091053 | 002 | Jan 06, 2011 | Mar | CAHN |
| >A> | | @ | 100MG | A091053 | 003 | Jan 06, 2011 | Mar | CAHN |

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTAPAP

| | | | | | | | | |
|-----|----|-------------------|------------|---------|-----|--------------|-----|------|
| >D> | AA | ! ANDA REPOSITORY | 325MG;50MG | A089987 | 001 | Oct 26, 1992 | Mar | CAHN |
| >A> | AA | ! MIKART | 325MG;50MG | A089987 | 001 | Oct 26, 1992 | Mar | CAHN |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | | | |
|-----|----|------------------|-------------|---------|-----|--------------|-----|------|
| >D> | | @ LANNETT CO INC | 300MG;5MG | A207171 | 001 | Jun 20, 2017 | Mar | CMFD |
| >A> | AA | | 300MG;5MG | A207171 | 001 | Jun 20, 2017 | Mar | CMFD |
| >D> | | @ | 300MG;7.5MG | A207171 | 002 | Jun 20, 2017 | Mar | CMFD |
| >A> | AA | | 300MG;7.5MG | A207171 | 002 | Jun 20, 2017 | Mar | CMFD |
| >D> | | @ | 300MG;10MG | A207171 | 003 | Jun 20, 2017 | Mar | CMFD |
| >A> | AA | | 300MG;10MG | A207171 | 003 | Jun 20, 2017 | Mar | CMFD |
| >D> | | @ | 325MG;5MG | A207172 | 001 | Jun 22, 2017 | Mar | CMFD |
| >A> | AA | | 325MG;5MG | A207172 | 001 | Jun 22, 2017 | Mar | CMFD |
| >D> | | @ | 325MG;7.5MG | A207172 | 002 | Jun 22, 2017 | Mar | CMFD |
| >A> | AA | | 325MG;7.5MG | A207172 | 002 | Jun 22, 2017 | Mar | CMFD |
| >D> | | @ | 325MG;10MG | A207172 | 003 | Jun 22, 2017 | Mar | CMFD |
| >A> | AA | | 325MG;10MG | A207172 | 003 | Jun 22, 2017 | Mar | CMFD |

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

| | | | | | | | | |
|-----|--|------------|-----------|---------|-----|--------------|-----|------|
| >A> | | +! AZURITY | 0.4MG/INH | N202450 | 001 | Jul 23, 2012 | Mar | CAHN |
| >D> | | +! COVIS | 0.4MG/INH | N202450 | 001 | Jul 23, 2012 | Mar | CAHN |

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

| | | | | | | | | |
|-----|--|------------|-----------------------|---------|-----|--------------|-----|------|
| >A> | | +! AZURITY | 0.4MG/INH;0.012MG/INH | N210595 | 001 | Mar 29, 2019 | Mar | CAHN |
| >D> | | +! COVIS | 0.4MG/INH;0.012MG/INH | N210595 | 001 | Mar 29, 2019 | Mar | CAHN |

ALBUTEROL SULFATE

TABLET;ORAL

ALBUTEROL SULFATE

| | | | | | | | | |
|-----|----|-------------------|-------------|---------|-----|--------------|-----|------|
| >D> | AB | DASH PHARMS NATCO | EQ 2MG BASE | A072894 | 002 | Jan 17, 1991 | Mar | CAHN |
| >D> | AB | ! | EQ 4MG BASE | A072894 | 001 | Jan 17, 1991 | Mar | CAHN |
| >A> | AB | NATCO PHARMA USA | EQ 2MG BASE | A072894 | 002 | Jan 17, 1991 | Mar | CAHN |
| >A> | AB | ! | EQ 4MG BASE | A072894 | 001 | Jan 17, 1991 | Mar | CAHN |

AMIFOSTINE

INJECTABLE;INJECTION

ETHYOL

| | | | | | | | | |
|-----|--|-----------------|------------|---------|-----|--------------|-----|------|
| >D> | | @ COSETTE | 375MG/VIAL | N020221 | 002 | Sep 10, 1999 | Mar | CAHN |
| >D> | | + @ | 500MG/VIAL | N020221 | 001 | Dec 08, 1995 | Mar | CAHN |
| >A> | | @ LEGACY PHARMA | 375MG/VIAL | N020221 | 002 | Sep 10, 1999 | Mar | CAHN |
| >A> | | + @ | 500MG/VIAL | N020221 | 001 | Dec 08, 1995 | Mar | CAHN |
| >A> | | +! | 500MG/VIAL | N020221 | 001 | Dec 08, 1995 | Mar | CMFD |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

| | | | | | | | | |
|-----|----|----------|----------|----------|-----|--------------|-----|------|
| >D> | AP | GEN ILAC | 250MG/ML | A 215374 | 001 | Aug 28, 2025 | Mar | CAHN |
| >A> | AP | ZENARA | 250MG/ML | A 215374 | 001 | Aug 28, 2025 | Mar | CAHN |

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|------------------------|-------|----------|-----|--------------|-----|------|
| >D> | | @ AUROBINDO PHARMA USA | 10MG | A 086009 | 002 | Apr 26, 1978 | Mar | CMFD |
| >A> | AB | | 10MG | A 086009 | 002 | Apr 26, 1978 | Mar | CMFD |
| >D> | | @ | 25MG | A 086009 | 003 | Apr 10, 1978 | Mar | CMFD |
| >A> | AB | | 25MG | A 086009 | 003 | Apr 10, 1978 | Mar | CMFD |
| >D> | | @ | 50MG | A 086009 | 001 | Apr 10, 1978 | Mar | CMFD |
| >A> | AB | | 50MG | A 086009 | 001 | Apr 10, 1978 | Mar | CMFD |
| >D> | | @ | 75MG | A 086009 | 004 | Apr 10, 1978 | Mar | CMFD |
| >A> | AB | | 75MG | A 086009 | 004 | Apr 10, 1978 | Mar | CMFD |
| >D> | | @ | 100MG | A 086009 | 005 | Apr 26, 1978 | Mar | CMFD |
| >A> | AB | | 100MG | A 086009 | 005 | Apr 26, 1978 | Mar | CMFD |
| >D> | | @ | 150MG | A 086009 | 006 | Apr 26, 1978 | Mar | CMFD |
| >A> | AB | | 150MG | A 086009 | 006 | Apr 26, 1978 | Mar | CMFD |

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET; ORAL

WIDAPLIK

| | | | | | | | | |
|-----|--|-------------|----------------------------------|----------|-----|--------------|-----|------|
| >D> | | + @ AZURITY | EQ 1.25MG BASE; 0.625MG; 10MG | N 219423 | 001 | Jun 05, 2025 | Mar | CMFD |
| >A> | | + | EQ 1.25MG BASE; 0.625MG; 10MG | N 219423 | 001 | Jun 05, 2025 | Mar | CMFD |
| >D> | | + @ | EQ 2.5MG BASE; 1.25MG; 20MG | N 219423 | 002 | Jun 05, 2025 | Mar | CMFD |
| >A> | | + | EQ 2.5MG BASE; 1.25MG; 20MG | N 219423 | 002 | Jun 05, 2025 | Mar | CMFD |
| >D> | | + @ | EQ 5MG BASE; 2.5MG; 40MG | N 219423 | 003 | Jun 05, 2025 | Mar | CMFD |
| >A> | | + | EQ 5MG BASE; 2.5MG; 40MG | N 219423 | 003 | Jun 05, 2025 | Mar | CMFD |

APREPITANT

EMULSION; INTRAVENOUS

APONVIE

| | | | | | | | | |
|-----|----|---------------------|-----------------------|----------|-----|--------------|-----|------|
| >D> | AB | ! HERON THERAPS INC | 32MG/4.4ML (7.2MG/ML) | N 216457 | 001 | Sep 16, 2022 | Mar | CTEC |
| >A> | | ! | 32MG/4.4ML (7.2MG/ML) | N 216457 | 001 | Sep 16, 2022 | Mar | CTEC |
| >D> | AB | MYLAN | 32MG/4.4ML (7.2MG/ML) | A 218851 | 001 | Mar 05, 2026 | Mar | DISC |
| >A> | | @ | 32MG/4.4ML (7.2MG/ML) | A 218851 | 001 | Mar 05, 2026 | Mar | DISC |

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

| | | | | | | | | |
|-----|----|------------|---------------|----------|-----|--------------|-----|------|
| >A> | AB | + ABBVIE | EQ 2.5MG BASE | N 022117 | 003 | Mar 12, 2015 | Mar | CAHN |
| >A> | AB | + | EQ 5MG BASE | N 022117 | 001 | Aug 13, 2009 | Mar | CAHN |
| >A> | AB | ! | EQ 10MG BASE | N 022117 | 002 | Aug 13, 2009 | Mar | CAHN |
| >D> | AB | + ALLERGAN | EQ 2.5MG BASE | N 022117 | 003 | Mar 12, 2015 | Mar | CAHN |
| >D> | AB | + | EQ 5MG BASE | N 022117 | 001 | Aug 13, 2009 | Mar | CAHN |
| >D> | AB | ! | EQ 10MG BASE | N 022117 | 002 | Aug 13, 2009 | Mar | CAHN |

ATOMOXETINE HYDROCHLORIDE

SOLUTION; ORAL

ATONCY

| | | | | | | | | |
|-----|--|---------|----------------|----------|-----|--------------|-----|------|
| >A> | | ! MAP77 | EQ 4MG BASE/ML | N 220320 | 001 | Mar 20, 2026 | Mar | NEWA |
|-----|--|---------|----------------|----------|-----|--------------|-----|------|

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

| | | | | | | | | |
|-----|--|--------------|--------------|----------|-----|--------------|-----|------|
| >D> | | ! PADAGIS US | 500 UNITS/GM | A 061212 | 001 | Nov 09, 1971 | Mar | DISC |
| >A> | | @ | 500 UNITS/GM | A 061212 | 001 | Nov 09, 1971 | Mar | DISC |

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

| | | | | | | | | |
|-----|--|--------------|--|----------|-----|--------------|-----|------|
| >D> | | ! PADAGIS US | 400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM | A 062166 | 002 | Apr 14, 1981 | Mar | DISC |
| >A> | | @ | 400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM | A 062166 | 002 | Apr 14, 1981 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

| | | | | | | | |
|-----|----|------------|--|--------------|--------------|-----|------|
| >D> | AT | PADAGIS US | 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A 060764 002 | Jan 22, 1981 | Mar | DISC |
| >A> | | @ | 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A 060764 002 | Jan 22, 1981 | Mar | DISC |

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

| | | | | | | | |
|-----|----|-------------------|---------------------------------|--------------|--------------|-----|------|
| >D> | AT | ! BAUSCH AND LOMB | 500 UNITS/GM;10,000 UNITS/GM | A 064046 001 | Jan 26, 1995 | Mar | CTEC |
| >A> | | ! | 500 UNITS/GM;10,000 UNITS/GM | A 064046 001 | Jan 26, 1995 | Mar | CTEC |
| >D> | AT | PADAGIS US | 500 UNITS/GM;10,000 UNITS/GM | A 065022 001 | Feb 27, 2002 | Mar | DISC |
| >A> | | @ | 500 UNITS/GM;10,000 UNITS/GM | A 065022 001 | Feb 27, 2002 | Mar | DISC |

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|-----|----|--------|-------------|--------------|--------------|-----|------|
| >D> | AB | APOTEX | 5MG;6.25MG | A 078794 001 | Aug 21, 2014 | Mar | DISC |
| >A> | | @ | 5MG;6.25MG | A 078794 001 | Aug 21, 2014 | Mar | DISC |
| >D> | AB | | 10MG;12.5MG | A 078794 002 | Aug 21, 2014 | Mar | DISC |
| >A> | | @ | 10MG;12.5MG | A 078794 002 | Aug 21, 2014 | Mar | DISC |
| >D> | AB | | 20MG;12.5MG | A 078794 003 | Aug 21, 2014 | Mar | DISC |
| >A> | | @ | 20MG;12.5MG | A 078794 003 | Aug 21, 2014 | Mar | DISC |
| >D> | AB | | 20MG;25MG | A 078794 004 | Aug 21, 2014 | Mar | DISC |
| >A> | | @ | 20MG;25MG | A 078794 004 | Aug 21, 2014 | Mar | DISC |

BENDAMUSTINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

| | | | | | | | |
|-----|--|-------------------|---------------------|-------------|--------------|-----|------|
| >A> | | +! AVYXA HOLDINGS | 100MG/4ML (25MG/ML) | N219014 001 | Jul 03, 2025 | Mar | CAHN |
| >D> | | + @ DR REDDYS | 100MG/4ML (25MG/ML) | N219014 001 | Jul 03, 2025 | Mar | CAHN |

BENZONATATE

CAPSULE;ORAL

BENZONATATE

| | | | | | | | |
|-----|----|-----------------|-------|--------------|--------------|-----|------|
| >A> | AA | MARKSANS PHARMA | 100MG | A 220298 001 | Mar 30, 2026 | Mar | NEWA |
| >A> | AA | | 200MG | A 220298 002 | Mar 30, 2026 | Mar | NEWA |

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

| | | | | | | | |
|-----|--|---------------------|------|--------------|--------------|-----|------|
| >D> | | @ DASH PHARMS NATCO | 5MG | A 075831 001 | Dec 14, 2005 | Mar | CAHN |
| >D> | | @ | 10MG | A 075831 002 | Dec 14, 2005 | Mar | CAHN |
| >A> | | @ NATCO PHARMA USA | 5MG | A 075831 001 | Dec 14, 2005 | Mar | CAHN |
| >A> | | @ | 10MG | A 075831 002 | Dec 14, 2005 | Mar | CAHN |

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|-----|----|--------------|--------------|--------------|--------------|-----|------|
| >A> | AB | UNIQUE PHARM | 2.5MG;6.25MG | A 219489 001 | Mar 24, 2026 | Mar | NEWA |
| >A> | AB | | 5MG;6.25MG | A 219489 002 | Mar 24, 2026 | Mar | NEWA |
| >A> | AB | | 10MG;6.25MG | A 219489 003 | Mar 24, 2026 | Mar | NEWA |

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

| | | | | | | | |
|-----|----|-----------------|------------|--------------|--------------|-----|------|
| >D> | AP | CAPLIN ONE LABS | 3.5MG/VIAL | A 203654 001 | Jul 26, 2022 | Mar | DISC |
| >A> | | @ | 3.5MG/VIAL | A 203654 001 | Jul 26, 2022 | Mar | DISC |

BRIVARACETAM

SOLUTION;ORAL

BRIVARACETAM

| | | | | | | | |
|-----|----|-----------------|---------|--------------|--------------|-----|------|
| >D> | AA | INDOCO | 10MG/ML | A 220385 001 | Feb 23, 2026 | Mar | CAHN |
| >A> | AA | REGCON HOLDINGS | 10MG/ML | A 220385 001 | Feb 23, 2026 | Mar | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

BUPRENORPHINE

SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS
BRIXADI

| | | | | | | | | |
|-----|---|----------|------------------------|---------|-----|--------------|-----|------|
| >D> | + | BRAEBURN | 8MG/0.16ML (50MG/ML) | N210136 | 001 | May 23, 2023 | Mar | CHRS |
| >A> | + | ! | 8MG/0.16ML (50MG/ML) | N210136 | 001 | May 23, 2023 | Mar | CHRS |
| >D> | + | | 16MG/0.32ML (50MG/ML) | N210136 | 002 | May 23, 2023 | Mar | CHRS |
| >A> | + | ! | 16MG/0.32ML (50MG/ML) | N210136 | 002 | May 23, 2023 | Mar | CHRS |
| >D> | + | | 24MG/0.48ML (50MG/ML) | N210136 | 003 | May 23, 2023 | Mar | CHRS |
| >A> | + | ! | 24MG/0.48ML (50MG/ML) | N210136 | 003 | May 23, 2023 | Mar | CHRS |
| >D> | + | | 32MG/0.64ML (50MG/ML) | N210136 | 004 | May 23, 2023 | Mar | CHRS |
| >A> | + | ! | 32MG/0.64ML (50MG/ML) | N210136 | 004 | May 23, 2023 | Mar | CHRS |
| >D> | + | | 64MG/0.18ML (356MG/ML) | N210136 | 005 | May 23, 2023 | Mar | CHRS |
| >A> | + | ! | 64MG/0.18ML (356MG/ML) | N210136 | 005 | May 23, 2023 | Mar | CHRS |
| >D> | + | | 96MG/0.27ML (356MG/ML) | N210136 | 006 | May 23, 2023 | Mar | CHRS |
| >A> | + | ! | 96MG/0.27ML (356MG/ML) | N210136 | 006 | May 23, 2023 | Mar | CHRS |

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL
ERGOTAMINE TARTRATE AND CAFFEINE

| | | | | | | | | |
|-----|---|-----------------|-----------|---------|-----|--------------|-----|------|
| >D> | ! | ANDA REPOSITORY | 100MG;1MG | A040590 | 001 | Sep 16, 2005 | Mar | CAHN |
| >A> | ! | MIKART | 100MG;1MG | A040590 | 001 | Sep 16, 2005 | Mar | CAHN |

CALCIUM ACETATE

CAPSULE; ORAL
CALCIUM ACETATE

| | | | | | | | | |
|-----|----|-----------|-------|---------|-----|--------------|-----|------|
| >D> | AB | LUPIN LTD | 667MG | A202127 | 001 | Jul 09, 2015 | Mar | DISC |
| >A> | | @ | 667MG | A202127 | 001 | Jul 09, 2015 | Mar | DISC |

TABLET; ORAL
CALCIUM ACETATE

| | | | | | | | | |
|-----|----|------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | PADAGIS US | 667MG | A091561 | 001 | Apr 13, 2011 | Mar | DISC |
| >A> | | @ | 667MG | A091561 | 001 | Apr 13, 2011 | Mar | DISC |

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10%

| | | | | | | | | |
|-----|----|-------------------|----------|---------|-----|--------------|-----|------|
| >D> | AP | SQUARE PHARMS PLC | 100MG/ML | A217463 | 001 | Sep 29, 2025 | Mar | DISC |
| >A> | | @ | 100MG/ML | A217463 | 001 | Sep 29, 2025 | Mar | DISC |

CEFIXIME

CAPSULE; ORAL
CEFIXIME

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | AUROBINDO PHARMA LTD | 400MG | A217607 | 001 | Mar 23, 2026 | Mar | NEWA |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL
CETIRIZINE HYDROCHLORIDE

| | | | | | | | | |
|-----|--|-----------------|---------|---------|-----|--------------|-----|------|
| >A> | | @ TIME CAP LABS | 5MG/5ML | A078757 | 001 | Aug 28, 2009 | Mar | CAHN |
| >D> | | @ WOCKHARDT | 5MG/5ML | A078757 | 001 | Aug 28, 2009 | Mar | CAHN |

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|------|------|---------|-----|--------------|-----|------|
| >D> | AB | BARR | 5MG | A084768 | 001 | Jun 10, 1976 | Mar | CRLD |
| >A> | AB | + | 5MG | A084768 | 001 | Jun 10, 1976 | Mar | CRLD |
| >D> | AB | | 10MG | A083116 | 001 | Jun 10, 1976 | Mar | CRLD |
| >A> | AB | + | 10MG | A083116 | 001 | Jun 10, 1976 | Mar | CRLD |
| >D> | AB | ! | 25MG | A084769 | 001 | Jun 10, 1976 | Mar | CRLD |
| >A> | AB | + | 25MG | A084769 | 001 | Jun 10, 1976 | Mar | CRLD |

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | | | | |
|-----|---|------------|----------------------------|---------|-----|--------------|-----|------|
| >D> | ! | PADAGIS US | 4MG/5ML; 5MG/5ML; 60MG/5ML | A204627 | 001 | Apr 29, 2014 | Mar | DISC |
| >A> | | @ | 4MG/5ML; 5MG/5ML; 60MG/5ML | A204627 | 001 | Apr 29, 2014 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

| | | | | | | | | | |
|----------|----|---|-----------------|----------|---------|-----|--------------|-----|------|
| >D> | AB | ! | GENUS | 30MG/ML | A214542 | 001 | Jun 02, 2021 | Mar | CTEC |
| >A> | AA | ! | | 30MG/ML | A214542 | 001 | Jun 02, 2021 | Mar | CTEC |
| >D> | AB | ! | | 100MG/ML | A214542 | 002 | Jun 02, 2021 | Mar | CTEC |
| >A> | AA | ! | | 100MG/ML | A214542 | 002 | Jun 02, 2021 | Mar | CTEC |
| >D> | AB | | RUBICON | 30MG/ML | A216678 | 001 | Oct 10, 2025 | Mar | CTEC |
| >A> | AA | | | 30MG/ML | A216678 | 001 | Oct 10, 2025 | Mar | CTEC |
| >D> | AB | | | 100MG/ML | A216678 | 002 | Oct 10, 2025 | Mar | CTEC |
| >A> | AA | | | 100MG/ML | A216678 | 002 | Oct 10, 2025 | Mar | CTEC |
| SONAZINE | | | | | | | | | |
| >D> | | @ | SAPTALIS PHARMS | 30MG/ML | A080983 | 004 | May 26, 1976 | Mar | CMFD |
| >A> | AA | | | 30MG/ML | A080983 | 004 | May 26, 1976 | Mar | CMFD |
| >D> | | @ | | 100MG/ML | A080983 | 005 | May 26, 1976 | Mar | CMFD |
| >A> | AA | | | 100MG/ML | A080983 | 005 | May 26, 1976 | Mar | CMFD |

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

| | | | | | | | | | |
|-----|----|---|----------------|------|---------|-----|--------------|-----|------|
| >D> | AB | | ALKEM LABS LTD | 50MG | A213412 | 002 | Feb 11, 2020 | Mar | CHRS |
| >A> | AB | ! | | 50MG | A213412 | 002 | Feb 11, 2020 | Mar | CHRS |

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

| | | | | | | | | | |
|-----|----|--|--------------|---------------------|---------|-----|--------------|-----|------|
| >A> | AB | | ZYDUS PHARMS | EQ 4GM RESIN/PACKET | A202902 | 002 | Apr 25, 2017 | Mar | NEWA |
|-----|----|--|--------------|---------------------|---------|-----|--------------|-----|------|

CICLESONIDE

AEROSOL, METERED; NASAL

ZETONNA

| | | | | | | | | | |
|-----------------------|--|---|-----------|--------------|---------|-----|--------------|-----|------|
| >A> | | + | @ AZURITY | 0.037MG/INH | N202129 | 001 | Jan 20, 2012 | Mar | CAHN |
| >D> | | + | @ COVIS | 0.037MG/INH | N202129 | 001 | Jan 20, 2012 | Mar | CAHN |
| SPRAY, METERED; NASAL | | | | | | | | | |
| OMNARIS | | | | | | | | | |
| >A> | | + | ! AZURITY | 0.05MG/SPRAY | N022004 | 001 | Oct 20, 2006 | Mar | CAHN |
| >D> | | + | ! COVIS | 0.05MG/SPRAY | N022004 | 001 | Oct 20, 2006 | Mar | CAHN |

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|---|--------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | | AMNEAL | EQ 250MG BASE | A075939 | 002 | Jun 09, 2004 | Mar | DISC |
| >A> | | @ | | EQ 250MG BASE | A075939 | 002 | Jun 09, 2004 | Mar | DISC |
| >D> | AB | | | EQ 500MG BASE | A075939 | 003 | Jun 09, 2004 | Mar | DISC |
| >A> | | @ | | EQ 500MG BASE | A075939 | 003 | Jun 09, 2004 | Mar | DISC |
| >D> | AB | | | EQ 750MG BASE | A075939 | 004 | Jun 09, 2004 | Mar | DISC |
| >A> | | @ | | EQ 750MG BASE | A075939 | 004 | Jun 09, 2004 | Mar | DISC |

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

| | | | | | | | | | |
|-----|----|---|----------------------|--------------|---------|-----|--------------|-----|------|
| >D> | | + | ! ALMATICA | EQ 30MG BASE | N215428 | 001 | Jan 31, 2022 | Mar | CFTG |
| >A> | AB | | ! | EQ 30MG BASE | N215428 | 001 | Jan 31, 2022 | Mar | CFTG |
| >A> | AB | | AUROBINDO PHARMA LTD | EQ 30MG BASE | A219985 | 001 | Mar 13, 2026 | Mar | NFTG |

CLADRIBINE

TABLET; ORAL

CLADRIBINE

| | | | | | | | | | |
|-----|----|--|-----------------|------|---------|-----|--------------|-----|------|
| >A> | AB | | HOPEWELL PHARMA | 10MG | A215547 | 001 | Mar 27, 2026 | Mar | NEWA |
|-----|----|--|-----------------|------|---------|-----|--------------|-----|------|

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|---|------------|------------------|---------|-----|--------------|-----|------|
| >D> | AA | | PADAGIS US | EQ 75MG BASE/5ML | A090902 | 001 | Jul 07, 2010 | Mar | DISC |
| >A> | | @ | | EQ 75MG BASE/5ML | A090902 | 001 | Jul 07, 2010 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

| | | | | | | | | |
|-----|-----|-----------------------|------------|---------|-----|--------------|-----|------|
| >A> | AB1 | AUROBINDO PHARMA LTD | EQ 1% BASE | A218942 | 001 | Mar 18, 2026 | Mar | NEWA |
| | | SOLUTION;TOPICAL | | | | | | |
| | | CLINDA-DERM | | | | | | |
| >D> | AT | PADAGIS US | EQ 1% BASE | A063329 | 001 | Sep 30, 1992 | Mar | DISC |
| >A> | | @ | EQ 1% BASE | A063329 | 001 | Sep 30, 1992 | Mar | DISC |
| | | CLINDAMYCIN PHOSPHATE | | | | | | |
| >A> | AT | RISING | EQ 1% BASE | A218300 | 001 | Mar 23, 2026 | Mar | NEWA |
| | | SWAB;TOPICAL | | | | | | |
| | | CLINDETS | | | | | | |
| >D> | AT | PADAGIS US | EQ 1% BASE | A064136 | 001 | Sep 30, 1996 | Mar | DISC |
| >A> | | @ PERRIGO CO | EQ 1% BASE | A064136 | 001 | Sep 30, 1996 | Mar | DISC |

CLOBETASOL PROPIONATE

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

| | | | | | | | | |
|-----|----|------------|-------|---------|-----|--------------|-----|------|
| >D> | AT | PADAGIS US | 0.05% | A090898 | 001 | Jun 16, 2011 | Mar | DISC |
| >A> | | @ | 0.05% | A090898 | 001 | Jun 16, 2011 | Mar | DISC |

CLONIDINE

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

| | | | | | | | | |
|-----|--|----------|----------------|---------|-----|--------------|-----|------|
| >D> | | ATHENA | EQ 0.17MG BASE | N022500 | 001 | Dec 03, 2009 | Mar | CAHN |
| >D> | | @ | EQ 0.26MG BASE | N022500 | 002 | Dec 03, 2009 | Mar | CAHN |
| >A> | | ROSEMONT | EQ 0.17MG BASE | N022500 | 001 | Dec 03, 2009 | Mar | CAHN |
| >A> | | @ | EQ 0.26MG BASE | N022500 | 002 | Dec 03, 2009 | Mar | CAHN |

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

| | | | | | | | | |
|-----|--|--------------------|--------|---------|-----|--------------|-----|------|
| >A> | | ! TP ANDA HOLDINGS | 0.05MG | A070923 | 004 | Apr 06, 2026 | Mar | NFTG |
|-----|--|--------------------|--------|---------|-----|--------------|-----|------|

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

| | | | | | | | | |
|-----|--|--------------------|--------|---------|-----|--------------|-----|------|
| >D> | | @ DASH PHARMS | 3.75MG | A071509 | 001 | Oct 19, 1987 | Mar | CAHN |
| >D> | | @ | 7.5MG | A071510 | 001 | Oct 19, 1987 | Mar | CAHN |
| >D> | | @ | 15MG | A071511 | 001 | Oct 19, 1987 | Mar | CAHN |
| >A> | | @ NATCO PHARMA USA | 3.75MG | A071509 | 001 | Oct 19, 1987 | Mar | CAHN |
| >A> | | @ | 7.5MG | A071510 | 001 | Oct 19, 1987 | Mar | CAHN |
| >A> | | @ | 15MG | A071511 | 001 | Oct 19, 1987 | Mar | CAHN |

COBICISTAT

TABLET;ORAL

TYBOST

| | | | | | | | | |
|-----|--|------------------------|-------|---------|-----|--------------|-----|------|
| >D> | | +! GILEAD SCIENCES INC | 150MG | N203094 | 001 | Sep 24, 2014 | Mar | DISC |
| >A> | | + @ | 150MG | N203094 | 001 | Sep 24, 2014 | Mar | DISC |

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

| | | | | | | | | |
|-----|--|-----------------|---------------------|---------|-----|--------------|-----|------|
| >D> | | + JANSSEN PRODS | 150MG;EQ 675MG BASE | N205395 | 002 | Mar 21, 2025 | Mar | CHRS |
| >A> | | +! | 150MG;EQ 675MG BASE | N205395 | 002 | Mar 21, 2025 | Mar | CHRS |

CUPRIC CHLORIDE

INJECTABLE;INJECTION

CUPRIC CHLORIDE

| | | | | | | | | |
|-----|----|--------|--------------------|---------|-----|--------------|-----|------|
| >D> | AP | AMNEAL | EQ 0.4MG COPPER/ML | A217287 | 001 | Jan 26, 2026 | Mar | DISC |
| >A> | | @ | EQ 0.4MG COPPER/ML | A217287 | 001 | Jan 26, 2026 | Mar | DISC |

CYCLOSPORINE

INJECTABLE;INJECTION

CYCLOSPORINE

| | | | | | | | | |
|-----|----|------------|---------|---------|-----|--------------|-----|------|
| >D> | AP | PADAGIS US | 50MG/ML | A065151 | 001 | Oct 07, 2003 | Mar | DISC |
| >A> | | @ | 50MG/ML | A065151 | 001 | Oct 07, 2003 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

| | | | | | | | |
|-----|-----------------------|-----|----------|-----|--------------|-----|------|
| >A> | @ ANVI | 4MG | A 087129 | 001 | Jul 09, 1981 | Mar | CAHN |
| >D> | @ STRIDES PHARMA INTL | 4MG | A 087129 | 001 | Jul 09, 1981 | Mar | CAHN |

DAPAGLIFLOZIN

TABLET; ORAL

DAPAGLIFLOZIN

| | | | | | | | |
|---------|----|---------------------|------|----------|-----|--------------|----------|
| >A> | | | | | | | |
| >A> | AB | AIZANT | 5MG | A 211523 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211523 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | AJANTA PHARMA LTD | 5MG | A 211482 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211482 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | ALEMBIC | 5MG | A 211560 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211560 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | ALKEM LABS LTD | 5MG | A 211545 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211545 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | AUROBINDO PHARMA | 5MG | A 211468 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211468 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | BIOCON PHARMA | 5MG | A 211470 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211470 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | CIPLA | 5MG | A 211535 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211535 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | INVENTIA | 5MG | A 211156 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211156 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | LUPIN LTD | 5MG | A 211531 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211531 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | MACLEODS PHARMS LTD | 5MG | A 211506 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211506 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | MICRO LABS | 5MG | A 211467 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211467 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | MSN | 5MG | A 211478 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211478 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | SANDOZ | 5MG | A 211312 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211312 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | TEVA PHARMS USA | 5MG | A 211541 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG | A 211541 | 002 | Apr 06, 2026 | Mar NFTG |
| >D> | | @ ZYDUS PHARMS | 5MG | A 211582 | 001 | Feb 22, 2022 | Mar NFTG |
| >A> | AB | | 5MG | A 211582 | 001 | Apr 06, 2026 | Mar NFTG |
| >D> | | @ | 10MG | A 211582 | 002 | Feb 22, 2022 | Mar NFTG |
| >A> | AB | | 10MG | A 211582 | 002 | Apr 06, 2026 | Mar NFTG |
| FARXIGA | | | | | | | |
| >D> | | + ASTRAZENECA AB | 5MG | N 202293 | 001 | Jan 08, 2014 | Mar CFTG |
| >A> | AB | | 5MG | N 202293 | 001 | Jan 08, 2014 | Mar CFTG |
| >D> | | + | 10MG | N 202293 | 002 | Jan 08, 2014 | Mar CFTG |
| >A> | AB | | 10MG | N 202293 | 002 | Jan 08, 2014 | Mar CFTG |

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

| | | | | | | | |
|-----|----|---------------------|-------------|----------|-----|--------------|----------|
| >A> | | | | | | | |
| >A> | AB | ALKEM LABS LTD | 5MG; 500MG | A 211563 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 5MG; 1GM | A 211563 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 500MG | A 211563 | 003 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 1GM | A 211563 | 004 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | AUROBINDO PHARMA | 5MG; 500MG | A 211489 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 5MG; 1GM | A 211489 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 500MG | A 211489 | 003 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 1GM | A 211489 | 004 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | CIPLA | 5MG; 1GM | A 211595 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | CIPLA LTD | 5MG; 500MG | A 211536 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 500MG | A 211536 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 1GM | A 211536 | 003 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | LUPIN LTD | 5MG; 500MG | A 211579 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 5MG; 1GM | A 211579 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 500MG | A 211579 | 003 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 1GM | A 211579 | 004 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | MACLEODS PHARMS LTD | 5MG; 500MG | A 211559 | 001 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 5MG; 1GM | A 211559 | 002 | Apr 06, 2026 | Mar NFTG |
| >A> | AB | | 10MG; 500MG | A 211559 | 003 | Apr 06, 2026 | Mar NFTG |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

| | | | | | | | | | |
|-----|---|---------------------|------------|---------|-----|--------------|-----|------|--|
| >A> | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | | | | | | | | |
| >A> | AB | | 10MG;1GM | A211559 | 004 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | MICRO LABS | 5MG;500MG | A211466 | 001 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 5MG;1GM | A211466 | 002 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;500MG | A211466 | 003 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;1GM | A211466 | 004 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | MSN | 5MG;500MG | A211479 | 001 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 5MG;1GM | A211479 | 002 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;500MG | A211479 | 003 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;1GM | A211479 | 004 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | SUN PHARM | 5MG;1GM | A211491 | 001 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;500MG | A211491 | 002 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;1GM | A211491 | 003 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | TEVA PHARMS USA INC | 2.5MG;1GM | A211583 | 001 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 5MG;500MG | A211583 | 002 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 5MG;1GM | A211583 | 003 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;500MG | A211583 | 004 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | | 10MG;1GM | A211583 | 005 | Apr 06, 2026 | Mar | NFTG | |
| | | XIGDUO XR | | | | | | | |
| >D> | | + ASTRAZENECA AB | 2.5MG;1GM | N205649 | 005 | Jul 28, 2017 | Mar | CFTG | |
| >A> | AB | + | 2.5MG;1GM | N205649 | 005 | Jul 28, 2017 | Mar | CFTG | |
| >D> | | + | 5MG;500MG | N205649 | 001 | Oct 29, 2014 | Mar | CFTG | |
| >A> | AB | + | 5MG;500MG | N205649 | 001 | Oct 29, 2014 | Mar | CFTG | |
| >D> | | + | 5MG;1GM | N205649 | 002 | Oct 29, 2014 | Mar | CFTG | |
| >A> | AB | + | 5MG;1GM | N205649 | 002 | Oct 29, 2014 | Mar | CFTG | |
| >D> | | + | 10MG;500MG | N205649 | 003 | Oct 29, 2014 | Mar | CFTG | |
| >A> | AB | + | 10MG;500MG | N205649 | 003 | Oct 29, 2014 | Mar | CFTG | |
| >D> | | + | 10MG;1GM | N205649 | 004 | Oct 29, 2014 | Mar | CFTG | |
| >A> | AB | + | 10MG;1GM | N205649 | 004 | Oct 29, 2014 | Mar | CFTG | |

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

| | | | | | | | | | |
|-----|---|---------|------------------|---------|-----|--------------|-----|------|--|
| >A> | DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE | | | | | | | | |
| >A> | AB | ! MSN | 10MG;EQ 5MG BASE | A211533 | 001 | Apr 06, 2026 | Mar | NFTG | |
| >A> | AB | TORRENT | 10MG;EQ 5MG BASE | A211537 | 001 | Apr 06, 2026 | Mar | NFTG | |

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

| | | | | | | | | | |
|-----|----|-------|------------|---------|-----|--------------|-----|------|--|
| >D> | AP | HIKMA | 500MG/VIAL | A078086 | 001 | May 30, 2007 | Mar | DISC | |
| >A> | | @ | 500MG/VIAL | A078086 | 001 | May 30, 2007 | Mar | DISC | |
| >D> | AP | | 2GM/VIAL | A078086 | 002 | May 30, 2007 | Mar | DISC | |
| >A> | | @ | 2GM/VIAL | A078086 | 002 | May 30, 2007 | Mar | DISC | |

DESLOMATADINE

TABLET;ORAL

DESLOMATADINE

| | | | | | | | | | |
|-----|--|--------------------|-----|---------|-----|--------------|-----|------|--|
| >D> | | @ DASH PHARMS | 5MG | A078351 | 001 | Feb 10, 2012 | Mar | CAHN | |
| >A> | | @ NATCO PHARMA USA | 5MG | A078351 | 001 | Feb 10, 2012 | Mar | CAHN | |

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

| | | | | | | | | | |
|-----|----|---------------|---------------|---------|-----|--------------|-----|------|--|
| >A> | AB | ANNORA PHARMA | 0.15MG;0.03MG | A219761 | 001 | Mar 18, 2026 | Mar | NEWA | |
|-----|----|---------------|---------------|---------|-----|--------------|-----|------|--|

DESOXIMETASONE

GEL;TOPICAL

DESOXIMETASONE

| | | | | | | | | | |
|-----|----|------------|-------|---------|-----|--------------|-----|------|--|
| >D> | AB | PADAGIS US | 0.05% | A077552 | 001 | Jan 09, 2006 | Mar | DISC | |
| >A> | | @ | 0.05% | A077552 | 001 | Jan 09, 2006 | Mar | DISC | |

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

| | | | | | | | | | |
|-----|----|--------------|---------------|---------|-----|--------------|-----|------|--|
| >D> | AB | MEDICAP LABS | EQ 50MG BASE | A204805 | 001 | May 07, 2019 | Mar | CAHN | |
| >D> | AB | | EQ 100MG BASE | A204805 | 002 | May 07, 2019 | Mar | CAHN | |
| >A> | AB | PLATINUM | EQ 50MG BASE | A204805 | 001 | May 07, 2019 | Mar | CAHN | |
| >A> | AB | | EQ 100MG BASE | A204805 | 002 | May 07, 2019 | Mar | CAHN | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

| | | | | | | |
|-----|----------|--------|--------------|--------------|-----|------|
| >D> | @ PANGEA | 0.25MG | A 088149 001 | Apr 28, 1983 | Mar | CMFD |
| >A> | | 0.25MG | A 088149 001 | Apr 28, 1983 | Mar | CMFD |

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

| | | | | | | | |
|-----|----|------------|--|--------------|--------------|-----|------|
| >D> | AT | PADAGIS US | 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A 062938 001 | Jul 31, 1989 | Mar | DISC |
| >A> | | @ | 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A 062938 001 | Jul 31, 1989 | Mar | DISC |

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | |
|-----|--|-----------------------|------|--------------|--------------|-----|------|
| >A> | | @ AUROLIFE PHARMA LLC | 5MG | A 202580 002 | Aug 25, 2015 | Mar | CMS1 |
| >A> | | @ | 10MG | A 202580 003 | Aug 25, 2015 | Mar | CMS1 |
| >A> | | @ | 15MG | A 202580 004 | Aug 25, 2015 | Mar | CMS1 |
| >A> | | @ | 20MG | A 202580 005 | Dec 21, 2015 | Mar | CMS1 |
| >A> | | @ | 25MG | A 202580 006 | May 04, 2021 | Mar | CMS1 |
| >A> | | @ | 35MG | A 202580 007 | May 04, 2021 | Mar | CMS1 |
| >A> | | @ | 40MG | A 202580 008 | Aug 25, 2015 | Mar | CMS1 |

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

| | | | | | | | |
|-----|----|---------------------|---------------------|--------------|--------------|-----|------|
| >A> | AA | HETERO LABS LTD III | 15MG/5ML;6.25MG/5ML | A 218264 001 | Mar 12, 2026 | Mar | NEWA |
|-----|----|---------------------|---------------------|--------------|--------------|-----|------|

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

| | | | | | | | |
|-----|----|--------|----|--------------|--------------|-----|------|
| >D> | AB | AMNEAL | 3% | A 200936 001 | Oct 28, 2013 | Mar | DISC |
| >A> | | @ | 3% | A 200936 001 | Oct 28, 2013 | Mar | DISC |

DIGOXIN

INJECTABLE; INJECTION

LANOXIN

| | | | | | | | |
|-----|----|-------------------|-----------|--------------|--------------|-----|------|
| >A> | AP | +! AZURITY | 0.25MG/ML | N 009330 002 | Nov 16, 1954 | Mar | CAHN |
| >D> | AP | +! COVIS | 0.25MG/ML | N 009330 002 | Nov 16, 1954 | Mar | CAHN |
| | | LANOXIN PEDIATRIC | | | | | |
| >A> | | +! AZURITY | 0.1MG/ML | N 009330 004 | Nov 16, 1954 | Mar | CAHN |
| >D> | | +! COVIS | 0.1MG/ML | N 009330 004 | Nov 16, 1954 | Mar | CAHN |

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

| | | | | | | | |
|-----|----|------------|--------|--------------|--------------|-----|------|
| >D> | AP | PADAGIS US | 1MG/ML | A 040475 001 | Apr 28, 2003 | Mar | DISC |
| >A> | | @ | 1MG/ML | A 040475 001 | Apr 28, 2003 | Mar | DISC |

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

DIMETHYL FUMARATE

| | | | | | | | |
|-----|----|-------|-------|--------------|--------------|-----|------|
| >D> | AB | MYLAN | 120MG | A 210531 001 | Aug 17, 2020 | Mar | DISC |
| >A> | | @ | 120MG | A 210531 001 | Aug 17, 2020 | Mar | DISC |
| >D> | AB | | 240MG | A 210531 002 | Aug 17, 2020 | Mar | DISC |
| >A> | | @ | 240MG | A 210531 002 | Aug 17, 2020 | Mar | DISC |

DISULFIRAM

TABLET; ORAL

DISULFIRAM

| | | | | | | | |
|-----|--|--------------------|-------|--------------|--------------|-----|------|
| >D> | | @ DASH PHARMS | 250MG | A 203916 001 | Mar 04, 2015 | Mar | CAHN |
| >D> | | @ | 500MG | A 203916 002 | Mar 04, 2015 | Mar | CAHN |
| >A> | | @ NATCO PHARMA USA | 250MG | A 203916 001 | Mar 04, 2015 | Mar | CAHN |
| >A> | | @ | 500MG | A 203916 002 | Mar 04, 2015 | Mar | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

| | | | | | | | | |
|-----|----|----------------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | PTS CONSULTING | EQ 10MG BASE | A217975 | 001 | Aug 21, 2023 | Mar | CAHN |
| >D> | AB | | EQ 25MG BASE | A217975 | 002 | Aug 21, 2023 | Mar | CAHN |
| >D> | AB | | EQ 50MG BASE | A217975 | 003 | Aug 21, 2023 | Mar | CAHN |
| >D> | AB | | EQ 75MG BASE | A217975 | 004 | Aug 21, 2023 | Mar | CAHN |
| >D> | AB | | EQ 100MG BASE | A217975 | 005 | Aug 21, 2023 | Mar | CAHN |
| >A> | AB | UNIQUE | EQ 10MG BASE | A217975 | 001 | Aug 21, 2023 | Mar | CAHN |
| >A> | AB | | EQ 25MG BASE | A217975 | 002 | Aug 21, 2023 | Mar | CAHN |
| >A> | AB | | EQ 50MG BASE | A217975 | 003 | Aug 21, 2023 | Mar | CAHN |
| >A> | AB | | EQ 75MG BASE | A217975 | 004 | Aug 21, 2023 | Mar | CAHN |
| >A> | AB | | EQ 100MG BASE | A217975 | 005 | Aug 21, 2023 | Mar | CAHN |

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

| | | | | | | | | |
|-----|----|--------------|--------------------|---------|-----|--------------|-----|------|
| >D> | AP | EUGIA PHARMA | 4MCG/2ML (2MCG/ML) | A213717 | 002 | Jan 24, 2022 | Mar | DISC |
| >A> | | @ | 4MCG/2ML (2MCG/ML) | A213717 | 002 | Jan 24, 2022 | Mar | DISC |
| >D> | AP | HIKMA | 4MCG/2ML (2MCG/ML) | A091101 | 001 | Aug 30, 2013 | Mar | DISC |
| >A> | | @ | 4MCG/2ML (2MCG/ML) | A091101 | 001 | Aug 30, 2013 | Mar | DISC |

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

DRONEDARONE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | LUPIN | EQ 400MG BASE | A205904 | 001 | Jan 31, 2024 | Mar | DISC |
| >A> | | @ | EQ 400MG BASE | A205904 | 001 | Jan 31, 2024 | Mar | DISC |
| >D> | AB | MULTAQ | EQ 400MG BASE | N022425 | 001 | Jul 01, 2009 | Mar | CTEC |
| >A> | | +! | EQ 400MG BASE | N022425 | 001 | Jul 01, 2009 | Mar | CTEC |

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

| | | | | | | | | |
|-----|----|------------------------|----|---------|-----|--------------|-----|------|
| >D> | | @ AUROBINDO PHARMA USA | 1% | A210364 | 001 | Apr 18, 2018 | Mar | CMFD |
| >A> | AB | | 1% | A210364 | 001 | Apr 18, 2018 | Mar | CMFD |

EFINACONAZOLE

SOLUTION; TOPICAL

EFINACONAZOLE

| | | | | | | | | |
|-----|----|--------------------|-----|---------|-----|--------------|-----|------|
| >A> | AB | NIVAGEN PHARMS INC | 10% | A211969 | 001 | Jun 21, 2021 | Mar | CAHN |
| >D> | AB | UMEDICA | 10% | A211969 | 001 | Jun 21, 2021 | Mar | CAHN |

ELTROMBOPAG OLAMINE

TABLET; ORAL

ELTROMBOPAG OLAMINE

| | | | | | | | | |
|-----|----|-----------|----------------|---------|-----|--------------|-----|------|
| >A> | AB | DR REDDYS | EQ 12.5MG ACID | A219121 | 001 | Mar 16, 2026 | Mar | NEWA |
| >A> | AB | | EQ 25MG ACID | A219121 | 002 | Mar 16, 2026 | Mar | NEWA |
| >A> | AB | | EQ 50MG ACID | A219121 | 003 | Mar 16, 2026 | Mar | NEWA |
| >A> | AB | | EQ 75MG ACID | A219121 | 004 | Mar 16, 2026 | Mar | NEWA |
| >A> | AB | ZENARA | EQ 12.5MG ACID | A220033 | 001 | Apr 08, 2026 | Mar | NEWA |
| >A> | AB | | EQ 25MG ACID | A220033 | 002 | Apr 08, 2026 | Mar | NEWA |
| >A> | AB | | EQ 50MG ACID | A220033 | 003 | Apr 08, 2026 | Mar | NEWA |
| >A> | AB | | EQ 75MG ACID | A220033 | 004 | Apr 08, 2026 | Mar | NEWA |

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

| | | | | | | | | |
|-----|----|---------------------|--------------------|---------|-----|--------------|-----|------|
| >D> | | | | | | | | |
| >D> | AB | LUPIN LTD | 200MG;EQ 25MG BASE | A213926 | 001 | Dec 13, 2024 | Mar | DISC |
| >A> | | @ | 200MG;EQ 25MG BASE | A213926 | 001 | Dec 13, 2024 | Mar | DISC |
| >A> | AB | MACLEODS PHARMS LTD | 200MG;EQ 25MG BASE | A214216 | 001 | Apr 07, 2026 | Mar | NEWA |

ENTECAVIR

TABLET; ORAL

ENTECAVIR

| | | | | | | | | |
|-----|--|---------------|-------|---------|-----|--------------|-----|------|
| >A> | | @ PHARMADAX | 0.5MG | A212106 | 001 | Aug 10, 2020 | Mar | CAHN |
| >A> | | @ | 1MG | A212106 | 002 | Aug 10, 2020 | Mar | CAHN |
| >D> | | @ SWISS PHARM | 0.5MG | A212106 | 001 | Aug 10, 2020 | Mar | CAHN |
| >D> | | @ | 1MG | A212106 | 002 | Aug 10, 2020 | Mar | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

>A> AP2 FRESINIUS KABI USA 50MG/10ML (5MG/ML) A219991 001 Mar 19, 2026 Mar NEWA

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

>A> +! BAXTER HLTHCARE CORP 1MG/ML (1MG/ML) N220626 001 Mar 30, 2026 Mar NEWA

>A> +! 30MG/30ML (1MG/ML) N220626 002 Mar 30, 2026 Mar NEWA

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

>A> +! BAXTER HLTHCARE CORP EQ 4MG BASE/250ML (EQ N218475 002 Mar 16, 2026 Mar NEWA
16MCG BASE/ML)

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

SOLUTION;INJECTION

FLAVALTA

>A> +! DEPROCO EQ 0.017MG BASE/1.7ML (EQ N216564 001 Mar 19, 2026 Mar NEWA
0.01MG BASE/ML);34MG/1.7ML
(20MG/ML)

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

ERIBULIN MESYLATE

>A> AP FORMOSA LABS 1MG/2ML (0.5MG/ML) A219054 001 Mar 16, 2026 Mar NEWA

>A> AP XGEN PHARMS 1MG/2ML (0.5MG/ML) A219054 001 Mar 16, 2026 Mar CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRACE

>A> AB +! ABBVIE 0.01% A086069 001 Jan 31, 1984 Mar CAHN

>D> AB +! ALLERGAN 0.01% A086069 001 Jan 31, 1984 Mar CAHN

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

>D> + NOVEN PHARMS INC 0.05MG/24HR;0.14MG/24HR N020870 001 Aug 07, 1998 Mar CHRS

>A> +! 0.05MG/24HR;0.14MG/24HR N020870 001 Aug 07, 1998 Mar CHRS

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

QUARTETTE

>D> AB +! TEVA BRANDED PHARM 0.02MG,0.15MG;0.025MG,0.15 N204061 001 Mar 28, 2013 Mar CAHN
MG;0.03MG,0.15MG;0.01MG,N/
A

>A> AB +! 0.02MG,0.15MG;0.025MG,0.15 N204061 001 Mar 28, 2013 Mar CAHN
MG;0.03MG,0.15MG;0.01MG,N/
A

ETOPOSIDE

INJECTABLE;INJECTION

ETOPOSIDE

>D> @ DASH PHARMS 20MG/ML A204927 001 Oct 31, 2017 Mar CAHN

>D> @ DASH PHARMS NATCO 20MG/ML A203507 001 Nov 20, 2017 Mar CAHN

>A> @ NATCO PHARMA USA 20MG/ML A203507 001 Nov 20, 2017 Mar CAHN

>A> @ 20MG/ML A204927 001 Oct 31, 2017 Mar CAHN

INJECTABLE;INTRAVENOUS

AVOPEF

>D> +! AVYXA HOLDINGS 100MG/5ML (20MG/ML) N220200 001 Feb 13, 2026 Mar CDFR

SOLUTION;INTRAVENOUS

AVOPEF

>A> +! AVYXA HOLDINGS 100MG/5ML (20MG/ML) N220200 001 Feb 13, 2026 Mar CDFR

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

>D> + @ ATHENA 35MG N022418 001 Aug 14, 2009 Mar CAHN

>D> + @ 105MG N022418 002 Aug 14, 2009 Mar CAHN

>A> + @ ROSEMONT 35MG N022418 001 Aug 14, 2009 Mar CAHN

>A> + @ 105MG N022418 002 Aug 14, 2009 Mar CAHN

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------------------|-------|----------|-----|--------------|-----|------|
| >D> | AB | DR REDDYS LABS LTD | 30MG | A 076502 | 001 | Apr 11, 2006 | Mar | DISC |
| >A> | | @ | 30MG | A 076502 | 001 | Apr 11, 2006 | Mar | DISC |
| >D> | AB | | 60MG | A 076502 | 002 | Apr 11, 2006 | Mar | DISC |
| >A> | | @ | 60MG | A 076502 | 002 | Apr 11, 2006 | Mar | DISC |
| >D> | AB | | 180MG | A 076502 | 003 | Apr 11, 2006 | Mar | DISC |
| >A> | | @ | 180MG | A 076502 | 003 | Apr 11, 2006 | Mar | DISC |
| >D> | AB | RISING | 60MG | A 077081 | 003 | Apr 11, 2008 | Mar | DISC |
| >A> | | @ | 60MG | A 077081 | 003 | Apr 11, 2008 | Mar | DISC |
| >D> | AB | | 180MG | A 077081 | 001 | Apr 16, 2007 | Mar | DISC |
| >A> | | @ | 180MG | A 077081 | 001 | Apr 16, 2007 | Mar | DISC |
| >D> | AB | TEVA | 30MG | A 076447 | 001 | Sep 01, 2005 | Mar | DISC |
| >A> | | @ | 30MG | A 076447 | 001 | Sep 01, 2005 | Mar | DISC |
| >D> | AB | | 60MG | A 076447 | 002 | Sep 01, 2005 | Mar | DISC |
| >A> | | @ | 60MG | A 076447 | 002 | Sep 01, 2005 | Mar | DISC |
| >D> | AB | | 180MG | A 076447 | 003 | Sep 01, 2005 | Mar | DISC |
| >A> | | @ | 180MG | A 076447 | 003 | Sep 01, 2005 | Mar | DISC |

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

| | | | | | | | | |
|-----|--|-------------------|---------------|----------|-----|--------------|-----|------|
| >A> | | +! LANTHEUS | 1.4-135mCi/ML | N 204677 | 001 | Mar 19, 2014 | Mar | CAHN |
| >D> | | +! LIFE MOLECULAR | 1.4-135mCi/ML | N 204677 | 001 | Mar 19, 2014 | Mar | CAHN |

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

| | | | | | | | | |
|-----|----|---------------------|-------|----------|-----|--------------|-----|------|
| >D> | AB | THINQ PHARM-CRO PVT | 50MG | A 076957 | 001 | Sep 28, 2005 | Mar | CAHN |
| >D> | AB | | 100MG | A 076957 | 002 | Sep 28, 2005 | Mar | CAHN |
| >D> | AB | | 150MG | A 076957 | 004 | Feb 27, 2017 | Mar | CAHN |
| >D> | AB | | 200MG | A 076957 | 003 | Sep 28, 2005 | Mar | CAHN |
| >A> | AB | UNIQUE | 50MG | A 076957 | 001 | Sep 28, 2005 | Mar | CAHN |
| >A> | AB | | 100MG | A 076957 | 002 | Sep 28, 2005 | Mar | CAHN |
| >A> | AB | | 150MG | A 076957 | 004 | Feb 27, 2017 | Mar | CAHN |
| >A> | AB | | 200MG | A 076957 | 003 | Sep 28, 2005 | Mar | CAHN |

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

| | | | | | | | | |
|-----|----|-------|----------------------|----------|-----|--------------|-----|------|
| >D> | AP | HIKMA | 0.5MG/5ML (0.1MG/ML) | A 076787 | 002 | Oct 12, 2004 | Mar | DISC |
| >A> | | @ | 0.5MG/5ML (0.1MG/ML) | A 076787 | 002 | Oct 12, 2004 | Mar | DISC |
| >D> | AP | | 1MG/10ML (0.1MG/ML) | A 076787 | 001 | Oct 12, 2004 | Mar | DISC |
| >A> | | @ | 1MG/10ML (0.1MG/ML) | A 076787 | 001 | Oct 12, 2004 | Mar | DISC |

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-----------|--------------|----------|-----|--------------|-----|------|
| >D> | AB | LUPIN LTD | EQ 60MG BASE | A 211632 | 001 | Feb 08, 2019 | Mar | DISC |
| >A> | | @ | EQ 60MG BASE | A 211632 | 001 | Feb 08, 2019 | Mar | DISC |

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

| | | | | | | | | |
|-----|----|------------------|----------------------------------|----------|-----|--------------|-----|------|
| >D> | AB | RESPIRENT PHARMS | 0.1MG/INH;EQ 0.05MG BASE/INH | A 214464 | 001 | Jan 12, 2026 | Mar | DISC |
| >A> | | @ | 0.1MG/INH;EQ 0.05MG BASE/INH | A 214464 | 001 | Jan 12, 2026 | Mar | DISC |
| >D> | AB | | 0.25MG/INH;EQ 0.05MG BASE/INH | A 214464 | 002 | Jan 12, 2026 | Mar | DISC |
| >A> | | @ | 0.25MG/INH;EQ 0.05MG BASE/INH | A 214464 | 002 | Jan 12, 2026 | Mar | DISC |

FOLIC ACID

SOLUTION; ORAL

QUIOFIC

| | | | | | | | | |
|-----|--|----------------|----------|----------|-----|--------------|-----|------|
| >D> | | +! CMP DEV LLC | 0.2MG/ML | N 216395 | 001 | Jan 26, 2026 | Mar | CAHN |
| >A> | | +! SOLUBIOMIX | 0.2MG/ML | N 216395 | 001 | Jan 26, 2026 | Mar | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

FONDAPARINUX SODIUM

SOLUTION; SUBCUTANEOUS

ARIXTRA

| | | | | | | | | | |
|-----|----|---|-------------------|---------------------------|---------|-----|--------------|-----|------|
| >D> | AP | + | MYLAN IRELAND LTD | 2.5MG/0.5ML | N021345 | 001 | Dec 07, 2001 | Mar | CPOT |
| >A> | AP | + | | 2.5MG/0.5ML (2.5MG/0.5ML) | N021345 | 001 | Dec 07, 2001 | Mar | CPOT |
| >D> | AP | + | | 5MG/0.4ML | N021345 | 002 | May 28, 2004 | Mar | CPOT |
| >A> | AP | + | | 5MG/0.4ML (5MG/0.4ML) | N021345 | 002 | May 28, 2004 | Mar | CPOT |
| >D> | AP | + | | 7.5MG/0.6ML | N021345 | 003 | May 28, 2004 | Mar | CPOT |
| >A> | AP | + | | 7.5MG/0.6ML (7.5MG/0.6ML) | N021345 | 003 | May 28, 2004 | Mar | CPOT |
| >D> | AP | + | | 10MG/0.8ML | N021345 | 004 | May 28, 2004 | Mar | CPOT |
| >A> | AP | + | | 10MG/0.8ML (10MG/0.8ML) | N021345 | 004 | May 28, 2004 | Mar | CPOT |

FONDAPARINUX SODIUM

| | | | | | | | | | |
|-----|----|---|--------------------|---------------------------|---------|-----|--------------|-----|------|
| >D> | | @ | BRIGHTGENE | 2.5MG/0.5ML | A218312 | 001 | Dec 18, 2024 | Mar | CPOT |
| >A> | | @ | | 2.5MG/0.5ML (2.5MG/0.5ML) | A218312 | 001 | Dec 18, 2024 | Mar | CPOT |
| >D> | AP | | DR REDDYS LABS LTD | 2.5MG/0.5ML | A091316 | 001 | Jul 11, 2011 | Mar | CPOT |
| >A> | AP | | | 2.5MG/0.5ML (2.5MG/0.5ML) | A091316 | 001 | Jul 11, 2011 | Mar | CPOT |
| >D> | AP | | | 5MG/0.4ML | A091316 | 002 | Jul 11, 2011 | Mar | CPOT |
| >A> | AP | | | 5MG/0.4ML (5MG/0.4ML) | A091316 | 002 | Jul 11, 2011 | Mar | CPOT |
| >D> | AP | | | 7.5MG/0.6ML | A091316 | 003 | Jul 11, 2011 | Mar | CPOT |
| >A> | AP | | | 7.5MG/0.6ML (7.5MG/0.6ML) | A091316 | 003 | Jul 11, 2011 | Mar | CPOT |
| >D> | AP | | | 10MG/0.8ML | A091316 | 004 | Jul 11, 2011 | Mar | CPOT |
| >A> | AP | | | 10MG/0.8ML (10MG/0.8ML) | A091316 | 004 | Jul 11, 2011 | Mar | CPOT |
| >D> | AP | | EUGIA PHARMA | 2.5MG/0.5ML | A206918 | 001 | Dec 26, 2017 | Mar | CPOT |
| >A> | AP | | | 2.5MG/0.5ML (2.5MG/0.5ML) | A206918 | 001 | Dec 26, 2017 | Mar | CPOT |
| >D> | AP | | | 5MG/0.4ML | A206918 | 002 | Dec 26, 2017 | Mar | CPOT |
| >A> | AP | | | 5MG/0.4ML (5MG/0.4ML) | A206918 | 002 | Dec 26, 2017 | Mar | CPOT |
| >D> | AP | | | 7.5MG/0.6ML | A206918 | 003 | Dec 26, 2017 | Mar | CPOT |
| >A> | AP | | | 7.5MG/0.6ML (7.5MG/0.6ML) | A206918 | 003 | Dec 26, 2017 | Mar | CPOT |
| >D> | AP | | | 10MG/0.8ML | A206918 | 004 | Dec 26, 2017 | Mar | CPOT |
| >A> | AP | | | 10MG/0.8ML (10MG/0.8ML) | A206918 | 004 | Dec 26, 2017 | Mar | CPOT |
| >D> | | @ | HANGZHOU ZHONGMEI | 2.5MG/0.5ML | A216493 | 001 | Aug 19, 2024 | Mar | CPOT |
| >A> | | @ | | 2.5MG/0.5ML (2.5MG/0.5ML) | A216493 | 001 | Aug 19, 2024 | Mar | CPOT |
| >D> | | @ | | 5MG/0.4ML | A216493 | 002 | Aug 19, 2024 | Mar | CPOT |
| >A> | | @ | | 5MG/0.4ML (5MG/0.4ML) | A216493 | 002 | Aug 19, 2024 | Mar | CPOT |
| >D> | | @ | | 7.5MG/0.6ML | A216493 | 003 | Aug 19, 2024 | Mar | CPOT |
| >A> | | @ | | 7.5MG/0.6ML (7.5MG/0.6ML) | A216493 | 003 | Aug 19, 2024 | Mar | CPOT |
| >D> | | @ | | 10MG/0.8ML | A216493 | 004 | Aug 19, 2024 | Mar | CPOT |
| >A> | | @ | | 10MG/0.8ML (10MG/0.8ML) | A216493 | 004 | Aug 19, 2024 | Mar | CPOT |
| >D> | AP | | HENGRUI PHARMA | 2.5MG/0.5ML | A206812 | 001 | May 15, 2018 | Mar | CPOT |
| >A> | AP | | | 2.5MG/0.5ML (2.5MG/0.5ML) | A206812 | 001 | May 15, 2018 | Mar | CPOT |
| >D> | AP | | | 5MG/0.4ML | A206812 | 002 | May 15, 2018 | Mar | CPOT |
| >A> | AP | | | 5MG/0.4ML (5MG/0.4ML) | A206812 | 002 | May 15, 2018 | Mar | CPOT |
| >D> | AP | | | 7.5MG/0.6ML | A206812 | 003 | May 15, 2018 | Mar | CPOT |
| >A> | AP | | | 7.5MG/0.6ML (7.5MG/0.6ML) | A206812 | 003 | May 15, 2018 | Mar | CPOT |
| >D> | AP | | | 10MG/0.8ML | A206812 | 004 | May 15, 2018 | Mar | CPOT |
| >A> | AP | | | 10MG/0.8ML (10MG/0.8ML) | A206812 | 004 | May 15, 2018 | Mar | CPOT |
| >D> | AP | | SCINOPHARM TAIWAN | 2.5MG/0.5ML | A208615 | 001 | Nov 14, 2018 | Mar | CPOT |
| >A> | AP | | | 2.5MG/0.5ML (2.5MG/0.5ML) | A208615 | 001 | Nov 14, 2018 | Mar | CPOT |
| >D> | AP | | | 5MG/0.4ML | A208615 | 002 | Nov 14, 2018 | Mar | CPOT |
| >A> | AP | | | 5MG/0.4ML (5MG/0.4ML) | A208615 | 002 | Nov 14, 2018 | Mar | CPOT |
| >D> | AP | | | 7.5MG/0.6ML | A208615 | 003 | Nov 14, 2018 | Mar | CPOT |
| >A> | AP | | | 7.5MG/0.6ML (7.5MG/0.6ML) | A208615 | 003 | Nov 14, 2018 | Mar | CPOT |
| >D> | AP | | | 10MG/0.8ML | A208615 | 004 | Nov 14, 2018 | Mar | CPOT |
| >A> | AP | | | 10MG/0.8ML (10MG/0.8ML) | A208615 | 004 | Nov 14, 2018 | Mar | CPOT |

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE

| | | | | | | | | | |
|-----|----|--|-------|--------------------|---------|-----|--------------|-----|------|
| >A> | AA | | AUCTA | EQ 3GM BASE/PACKET | A217772 | 001 | Apr 09, 2026 | Mar | NEWA |
|-----|----|--|-------|--------------------|---------|-----|--------------|-----|------|

FULVESTRANT

SOLUTION; INTRAMUSCULAR

FULVESTRANT

| | | | | | | | | | |
|-----|----|---|--------------|---------------------|---------|-----|--------------|-----|------|
| >D> | AO | | EUGIA PHARMA | 250MG/5ML (50MG/ML) | A215169 | 001 | Jun 30, 2023 | Mar | DISC |
| >A> | | @ | | 250MG/5ML (50MG/ML) | A215169 | 001 | Jun 30, 2023 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

CAPSULE; ORAL

| | | | | | | | | | |
|-----|----|----------------|-------|---------|-----|--------------|-----|------|--|
| >D> | | GABAPENTIN | | | | | | | |
| >D> | AB | SCIEGEN PHARMS | 100MG | A204989 | 001 | Feb 18, 2016 | Mar | CTNA | |
| >D> | | | 200MG | A204989 | 004 | Mar 06, 2026 | Mar | CTNA | |
| >D> | AB | | 300MG | A204989 | 002 | Feb 18, 2016 | Mar | CTNA | |
| >D> | AB | | 400MG | A204989 | 003 | Feb 18, 2016 | Mar | CTNA | |
| >A> | | RELGAABI | | | | | | | |
| >A> | AB | SCIEGEN PHARMS | 100MG | A204989 | 001 | Feb 18, 2016 | Mar | CTNA | |
| >A> | | | 200MG | A204989 | 004 | Mar 06, 2026 | Mar | CTNA | |
| >A> | AB | | 300MG | A204989 | 002 | Feb 18, 2016 | Mar | CTNA | |
| >A> | AB | | 400MG | A204989 | 003 | Feb 18, 2016 | Mar | CTNA | |

GANAXOLONE

SUSPENSION; ORAL

ZTALMY

| | | | | | | | | | |
|-----|--|--------------------|---------|---------|-----|--------------|-----|------|--|
| >A> | | +! IMMEDICA PHARMA | 50MG/ML | N215904 | 001 | Jun 01, 2022 | Mar | CAHN | |
| >D> | | +! MARINUS | 50MG/ML | N215904 | 001 | Jun 01, 2022 | Mar | CAHN | |

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

| | | | | | | | | | |
|-----|----|-----------------|--------------|---------|-----|--------------|-----|------|--|
| >D> | AP | TRIS PHARMA INC | 250MCG/0.5ML | A219454 | 001 | Jun 27, 2025 | Mar | DISC | |
| >A> | | @ | 250MCG/0.5ML | A219454 | 001 | Jun 27, 2025 | Mar | DISC | |

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

| | | | | | | | | | |
|-----|----|------------|--------------|---------|-----|--------------|-----|------|--|
| >D> | AT | PADAGIS US | EQ 0.3% BASE | A065121 | 001 | Jan 30, 2004 | Mar | DISC | |
| >A> | | @ | EQ 0.3% BASE | A065121 | 001 | Jan 30, 2004 | Mar | DISC | |

GLECAPREVIR; PIBRENTASVIR

PELLETS; ORAL

MAVYRET

| | | | | | | | | | |
|-----|--|-----------|--------------------------|---------|-----|--------------|-----|------|--|
| >D> | | +! ABBVIE | 50MG; 20MG/PACKET | N215110 | 001 | Jun 10, 2021 | Mar | CPOT | |
| >A> | | +! | 50MG/PACKET; 20MG/PACKET | N215110 | 001 | Jun 10, 2021 | Mar | CPOT | |

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|----------------|---------------|---------|-----|--------------|-----|------|--|
| >A> | AB | IMPAX | 1.25MG; 250MG | A076345 | 001 | Feb 18, 2004 | Mar | CAHN | |
| >A> | AB | | 2.5MG; 500MG | A076345 | 002 | Feb 18, 2004 | Mar | CAHN | |
| >A> | AB | | 5MG; 500MG | A076345 | 003 | Feb 18, 2004 | Mar | CAHN | |
| >D> | AB | IMPAX LABS INC | 1.25MG; 250MG | A076345 | 001 | Feb 18, 2004 | Mar | CAHN | |
| >D> | AB | | 2.5MG; 500MG | A076345 | 002 | Feb 18, 2004 | Mar | CAHN | |
| >D> | AB | | 5MG; 500MG | A076345 | 003 | Feb 18, 2004 | Mar | CAHN | |

GLYCOPYRRONIUM TOSYLATE

CLOTH; TOPICAL

GLYCOPYRRONIUM TOSYLATE

| | | | | | | | | | |
|-----|----|------------|--------------|---------|-----|--------------|-----|------|--|
| >A> | AB | PADAGIS US | EQ 2.4% BASE | A214448 | 001 | Apr 03, 2026 | Mar | NFTG | |
| >D> | | QBREXZA | | | | | | | |
| >D> | | +! JOURNEY | EQ 2.4% BASE | N210361 | 001 | Jun 28, 2018 | Mar | CFTG | |
| >A> | AB | +! | EQ 2.4% BASE | N210361 | 001 | Jun 28, 2018 | Mar | CFTG | |

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|-------------------|-------------|---------|-----|--------------|-----|------|--|
| >A> | AB | ASCENT PHARMS INC | EQ 1MG BASE | A220675 | 001 | Mar 24, 2026 | Mar | NEWA | |
| >A> | AB | | EQ 2MG BASE | A220675 | 002 | Mar 24, 2026 | Mar | NEWA | |
| >D> | BX | RUBICON RESEARCH | EQ 1MG BASE | A216762 | 001 | Oct 17, 2023 | Mar | CTEC | |
| >A> | AB | | EQ 1MG BASE | A216762 | 001 | Oct 17, 2023 | Mar | CTEC | |
| >D> | BX | | EQ 2MG BASE | A216762 | 002 | Oct 17, 2023 | Mar | CTEC | |
| >A> | AB | | EQ 2MG BASE | A216762 | 002 | Oct 17, 2023 | Mar | CTEC | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

| | | | | | | | | |
|-----|----|------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | AIPING PHARM INC | 0.5MG | A071130 | 004 | Apr 08, 2026 | Mar | NEWA |
| >A> | AB | | 1MG | A071130 | 005 | Apr 08, 2026 | Mar | NEWA |
| >A> | AB | | 20MG | A071130 | 006 | Apr 08, 2026 | Mar | NEWA |

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

| | | | | | | | | |
|-----|----|------------|-------------------|---------|-----|--------------|-----|------|
| >D> | AA | PADAGIS US | 1.5MG/5ML;5MG/5ML | A205731 | 001 | Feb 15, 2017 | Mar | DISC |
| >A> | | @ | 1.5MG/5ML;5MG/5ML | A205731 | 001 | Feb 15, 2017 | Mar | DISC |

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|----------|-------|---------|-----|--------------|-----|------|
| >D> | AA | HERITAGE | 10MG | A086242 | 001 | Feb 04, 2010 | Mar | DISC |
| >A> | | @ | 10MG | A086242 | 001 | Feb 04, 2010 | Mar | DISC |
| >D> | AA | | 25MG | A086242 | 003 | Oct 23, 1978 | Mar | DISC |
| >A> | | @ | 25MG | A086242 | 003 | Oct 23, 1978 | Mar | DISC |
| >D> | AA | | 50MG | A086242 | 002 | Oct 23, 1978 | Mar | DISC |
| >A> | | @ | 50MG | A086242 | 002 | Oct 23, 1978 | Mar | DISC |
| >D> | AA | | 100MG | A086242 | 004 | Feb 04, 2010 | Mar | DISC |
| >A> | | @ | 100MG | A086242 | 004 | Feb 04, 2010 | Mar | DISC |

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|-----|----|----------------|-------------|---------|-----|--------------|-----|------|
| >A> | AB | SCIEGEN PHARMS | 12.5MG;20MG | A208465 | 001 | Mar 31, 2026 | Mar | NEWA |
| >A> | AB | | 12.5MG;40MG | A208465 | 002 | Mar 31, 2026 | Mar | NEWA |
| >A> | AB | | 25MG;40MG | A208465 | 003 | Mar 31, 2026 | Mar | NEWA |

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

| | | | | | | | | |
|-----|----|----------------|------|---------|-----|--------------|-----|------|
| >D> | AB | PADAGIS ISRAEL | 0.2% | A075666 | 001 | May 24, 2000 | Mar | DISC |
| >A> | | @ | 0.2% | A075666 | 001 | May 24, 2000 | Mar | DISC |

>A> ICOTROKINRA HYDROCHLORIDE

>A> TABLET;ORAL

>A> ICOTYDE

| | | | | | | | | |
|-----|--|--------------------|---------------|---------|-----|--------------|-----|------|
| >A> | | +! JANSSEN BIOTECH | EQ 200MG BASE | N220149 | 001 | Mar 17, 2026 | Mar | NEWA |
|-----|--|--------------------|---------------|---------|-----|--------------|-----|------|

IMATINIB MESYLATE

TABLET;ORAL

GLEEVEC

| | | | | | | | | |
|-----|----|------------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | + NOVARTIS | EQ 100MG BASE | N021588 | 001 | Apr 18, 2003 | Mar | CHRS |
| >A> | AB | +! | EQ 100MG BASE | N021588 | 001 | Apr 18, 2003 | Mar | CHRS |
| >D> | AB | +! | EQ 400MG BASE | N021588 | 002 | Apr 18, 2003 | Mar | CHRS |
| >A> | AB | + | EQ 400MG BASE | N021588 | 002 | Apr 18, 2003 | Mar | CHRS |

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

| | | | | | | | | |
|-----|----|--------------|------|---------|-----|--------------|-----|------|
| >D> | | @ ANI PHARMS | 20MG | A075147 | 001 | Nov 27, 1998 | Mar | CMFD |
| >A> | AB | | 20MG | A075147 | 001 | Nov 27, 1998 | Mar | CMFD |

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

| | | | | | | | | |
|-----|-----|------------------|------|---------|-----|--------------|-----|------|
| >D> | AB2 | AMNEAL PHARMS NY | 10MG | A216097 | 001 | Oct 07, 2025 | Mar | DISC |
| >A> | | @ | 10MG | A216097 | 001 | Oct 07, 2025 | Mar | DISC |
| >D> | AB2 | | 20MG | A216097 | 002 | Oct 07, 2025 | Mar | DISC |
| >A> | | @ | 20MG | A216097 | 002 | Oct 07, 2025 | Mar | DISC |
| >D> | AB2 | | 25MG | A216097 | 003 | Oct 07, 2025 | Mar | DISC |
| >A> | | @ | 25MG | A216097 | 003 | Oct 07, 2025 | Mar | DISC |
| >D> | AB2 | | 30MG | A216097 | 004 | Oct 07, 2025 | Mar | DISC |
| >A> | | @ | 30MG | A216097 | 004 | Oct 07, 2025 | Mar | DISC |
| >D> | AB2 | | 35MG | A216097 | 005 | Oct 07, 2025 | Mar | DISC |
| >A> | | @ | 35MG | A216097 | 005 | Oct 07, 2025 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

ISOTRETINOIN

CAPSULE; ORAL
ISOTRETINOIN

| | | | | | | | | |
|-----|-----|--|------|---------|-----|--------------|-----|------|
| >D> | AB2 | | 40MG | A216097 | 006 | Oct 07, 2025 | Mar | DISC |
| >A> | @ | | 40MG | A216097 | 006 | Oct 07, 2025 | Mar | DISC |

IVABRADINE

SOLUTION; ORAL
CORLANOR

| | | | | | | | | |
|-----|---|-----------|------------------|---------|-----|--------------|-----|------|
| >D> | + | AMGEN INC | 5MG/5ML (1MG/ML) | N209964 | 001 | Apr 22, 2019 | Mar | DISC |
| >A> | + | @ | 5MG/5ML (1MG/ML) | N209964 | 001 | Apr 22, 2019 | Mar | DISC |

IVERMECTIN

TABLET; ORAL
IVERMECTIN

| | | | | | | | | |
|-----|----|-------------------|-----|---------|-----|--------------|-----|------|
| >A> | AB | AJANTA PHARMA LTD | 3MG | A218509 | 001 | Apr 07, 2026 | Mar | NEWA |
|-----|----|-------------------|-----|---------|-----|--------------|-----|------|

LABETALOL HYDROCHLORIDE

TABLET; ORAL
LABETALOL HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-----------------|-------|---------|-----|--------------|-----|------|
| >D> | | APPCO | 400MG | A209603 | 004 | Oct 18, 2024 | Mar | CTEC |
| >A> | AB | | 400MG | A209603 | 004 | Oct 18, 2024 | Mar | CTEC |
| >A> | AB | HERITAGE PHARMA | 400MG | A074787 | 004 | Mar 26, 2026 | Mar | NEWA |

LACOSAMIDE

SOLUTION; INTRAVENOUS
LACOSAMIDE

| | | | | | | | | |
|-----|----|-----------------|----------------------|---------|-----|--------------|-----|------|
| >D> | AP | ANTHEA PHARMA | 200MG/20ML (10MG/ML) | A220268 | 001 | Jan 21, 2026 | Mar | CAHN |
| >A> | AP | GLENMARK PHARMS | 200MG/20ML (10MG/ML) | A220268 | 001 | Jan 21, 2026 | Mar | CAHN |

LENALIDOMIDE

CAPSULE; ORAL
LENALIDOMIDE

| | | | | | | | | |
|-----|----|---------|-------|---------|-----|--------------|-----|------|
| >D> | AB | TORRENT | 2.5MG | A213405 | 005 | Feb 10, 2026 | Mar | DISC |
| >A> | @ | | 2.5MG | A213405 | 005 | Feb 10, 2026 | Mar | DISC |
| >D> | AB | | 5MG | A213405 | 006 | Feb 10, 2026 | Mar | DISC |
| >A> | @ | | 5MG | A213405 | 006 | Feb 10, 2026 | Mar | DISC |
| >D> | AB | | 15MG | A213405 | 004 | Nov 04, 2025 | Mar | DISC |
| >A> | @ | | 15MG | A213405 | 004 | Nov 04, 2025 | Mar | DISC |

LEVETIRACETAM

SOLUTION; ORAL
LEVETIRACETAM

| | | | | | | | | |
|-----|----|-----------------|----------|---------|-----|--------------|-----|------|
| >A> | AA | ANDA REPOSITORY | 100MG/ML | A218080 | 001 | Nov 21, 2025 | Mar | CAHN |
| >D> | AA | GUARDIAN DRUG | 100MG/ML | A218080 | 001 | Nov 21, 2025 | Mar | CAHN |

LEVOLEUCOVORIN CALCIUM

SOLUTION; INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

| | | | | | | | | |
|-----|----|--------|--|---------|-----|--------------|-----|------|
| >D> | AP | AMNEAL | EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) | A207548 | 001 | Sep 08, 2017 | Mar | DISC |
| >A> | @ | | EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) | A207548 | 001 | Sep 08, 2017 | Mar | DISC |

LIDOCAINE

PATCH; TOPICAL
LIDOCAINE

| | | | | | | | | |
|-----|----|----------|----|---------|-----|--------------|-----|------|
| >D> | @ | USPHARMA | 5% | A207059 | 001 | Feb 09, 2026 | Mar | CMFD |
| >A> | AB | | 5% | A207059 | 001 | Feb 09, 2026 | Mar | CMFD |

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------|----|---------|-----|--------------|-----|------|
| >A> | AP | VIWIT PHARM | 1% | A220071 | 001 | Mar 19, 2026 | Mar | NEWA |
| >A> | AP | | 2% | A220071 | 002 | Mar 19, 2026 | Mar | NEWA |

SOLUTION; ORAL
LIDOCAINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------|----|---------|-----|--------------|-----|------|
| >A> | AT | QUAGEN | 2% | A218676 | 001 | Mar 20, 2026 | Mar | NEWA |
|-----|----|--------|----|---------|-----|--------------|-----|------|

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

| | | | | | | | | | |
|-----|--|------------------------|--|---------|-----|--------------|-----|------|--|
| >A> | <u>LINERIXIBAT</u> | | | | | | | | |
| >A> | TABLET;ORAL | | | | | | | | |
| >A> | LYNAVOY | | | | | | | | |
| >A> | +! GLAXOSMITHKLINE | 40MG | | N220295 | 001 | Mar 17, 2026 | Mar | NEWA | |
| | <u>LIRAGLUTIDE</u> | | | | | | | | |
| | SOLUTION;SUBCUTANEOUS | | | | | | | | |
| | LIRAGLUTIDE | | | | | | | | |
| >A> | AP1 FRESENIUS KABI USA | 18MG/3ML (6MG/ML) | | A212552 | 001 | Mar 30, 2026 | Mar | NEWA | |
| | <u>LITHIUM CITRATE</u> | | | | | | | | |
| | SYRUP;ORAL | | | | | | | | |
| | LITHIUM CITRATE | | | | | | | | |
| >D> | @ PAI HOLDINGS PHARM | EQ 300MG CARBONATE/5ML | | A070755 | 001 | May 21, 1986 | Mar | CMFD | |
| >A> | AA | EQ 300MG CARBONATE/5ML | | A070755 | 001 | May 21, 1986 | Mar | CMFD | |
| | <u>LOMITAPIDE MESYLATE</u> | | | | | | | | |
| | CAPSULE;ORAL | | | | | | | | |
| | JUXTAPID | | | | | | | | |
| >D> | + CHIESI | EQ 30MG BASE | | N203858 | 004 | Apr 23, 2015 | Mar | CHRS | |
| >A> | +! | EQ 30MG BASE | | N203858 | 004 | Apr 23, 2015 | Mar | CHRS | |
| | <u>LOVASTATIN</u> | | | | | | | | |
| | TABLET, EXTENDED RELEASE;ORAL | | | | | | | | |
| | ALTOPREV | | | | | | | | |
| >A> | @ AZURITY | 10MG | | N021316 | 001 | Jun 26, 2002 | Mar | CAHN | |
| >A> | + @ | 20MG | | N021316 | 002 | Jun 26, 2002 | Mar | CAHN | |
| >A> | + @ | 40MG | | N021316 | 003 | Jun 26, 2002 | Mar | CAHN | |
| >A> | + @ | 60MG | | N021316 | 004 | Jun 26, 2002 | Mar | CAHN | |
| >D> | @ COVIS | 10MG | | N021316 | 001 | Jun 26, 2002 | Mar | CAHN | |
| >D> | + @ | 20MG | | N021316 | 002 | Jun 26, 2002 | Mar | CAHN | |
| >D> | + @ | 40MG | | N021316 | 003 | Jun 26, 2002 | Mar | CAHN | |
| >D> | + @ | 60MG | | N021316 | 004 | Jun 26, 2002 | Mar | CAHN | |
| | <u>MACITENTAN</u> | | | | | | | | |
| | TABLET;ORAL | | | | | | | | |
| | MACITENTAN | | | | | | | | |
| >D> | @ APOTEX | 10MG | | A211195 | 001 | Jan 09, 2024 | Mar | CMFD | |
| >A> | AB | 10MG | | A211195 | 001 | Jan 09, 2024 | Mar | CMFD | |
| | <u>MAGNESIUM SULFATE</u> | | | | | | | | |
| | INJECTABLE;INJECTION | | | | | | | | |
| | MAGNESIUM SULFATE IN PLASTIC CONTAINER | | | | | | | | |
| >D> | AP MYLAN LABS LTD | 2GM/50ML (40MG/ML) | | A209911 | 001 | Sep 14, 2018 | Mar | DISC | |
| >A> | @ | 2GM/50ML (40MG/ML) | | A209911 | 001 | Sep 14, 2018 | Mar | DISC | |
| | <u>MEMANTINE HYDROCHLORIDE</u> | | | | | | | | |
| | SOLUTION;ORAL | | | | | | | | |
| | MEMANTINE HYDROCHLORIDE | | | | | | | | |
| >A> | AA MEDLEY PHARMS | 2MG/ML | | A210319 | 001 | Aug 31, 2020 | Mar | CAHN | |
| >D> | AA SETON PHARMS | 2MG/ML | | A210319 | 001 | Aug 31, 2020 | Mar | CAHN | |
| | TABLET;ORAL | | | | | | | | |
| | MEMANTINE HYDROCHLORIDE | | | | | | | | |
| >D> | AB DR REDDYS LABS LTD | 10MG | | A090048 | 002 | Apr 14, 2010 | Mar | CHRS | |
| >A> | AB ! | 10MG | | A090048 | 002 | Apr 14, 2010 | Mar | CHRS | |
| | NAMENDA | | | | | | | | |
| >D> | AB + ABBVIE | 5MG | | N021487 | 001 | Oct 16, 2003 | Mar | DISC | |
| >A> | + @ | 5MG | | N021487 | 001 | Oct 16, 2003 | Mar | DISC | |
| >D> | AB +! | 10MG | | N021487 | 002 | Oct 16, 2003 | Mar | DISC | |
| >A> | + @ | 10MG | | N021487 | 002 | Oct 16, 2003 | Mar | DISC | |
| | <u>MESALAMINE</u> | | | | | | | | |
| | ENEMA;RECTAL | | | | | | | | |
| | MESALAMINE | | | | | | | | |
| >A> | AB KLM LABS PVT | 4GM/60ML | | A220016 | 001 | Mar 31, 2026 | Mar | NEWA | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|-----|-----|------------------|-------|----------|-----|--------------|-----|------|
| >D> | AB1 | AMNEAL PHARMS NY | 500MG | A 078596 | 001 | Jan 03, 2008 | Mar | DISC |
| >A> | | @ | 500MG | A 078596 | 001 | Jan 03, 2008 | Mar | DISC |
| >D> | AB | | 750MG | A 078596 | 002 | Jan 03, 2008 | Mar | DISC |
| >A> | | @ | 750MG | A 078596 | 002 | Jan 03, 2008 | Mar | DISC |

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

| | | | | | | | | |
|-----|----|------------|-------|----------|-----|--------------|-----|------|
| >A> | AA | DBL PHARMS | 500MG | A 203550 | 001 | Feb 08, 2017 | Mar | CAHN |
| >A> | AA | | 750MG | A 203550 | 002 | Feb 08, 2017 | Mar | CAHN |
| >D> | AA | HLTHCARE | 500MG | A 203550 | 001 | Feb 08, 2017 | Mar | CAHN |
| >D> | AA | | 750MG | A 203550 | 002 | Feb 08, 2017 | Mar | CAHN |

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

| | | | | | | | | |
|-----|----|-----------------|---------------------------|----------|-----|--------------|-----|------|
| >D> | AP | CAPLIN ONE LABS | EQ 50MG BASE/2ML (EQ 25MG | A 090039 | 001 | Mar 31, 2009 | Mar | DISC |
| >A> | | @ | BASE/ML) | A 090039 | 001 | Mar 31, 2009 | Mar | DISC |
| >D> | AP | | EQ 250MG BASE/10ML (EQ | A 090039 | 002 | Mar 31, 2009 | Mar | DISC |
| >A> | | @ | 25MG BASE/ML) | A 090039 | 002 | Mar 31, 2009 | Mar | DISC |
| >D> | AP | | EQ 250MG BASE/10ML (EQ | A 090039 | 002 | Mar 31, 2009 | Mar | DISC |
| >A> | | @ | 25MG BASE/ML) | A 090039 | 002 | Mar 31, 2009 | Mar | DISC |
| >D> | AP | | EQ 1GM BASE/40ML (EQ 25MG | A 090029 | 001 | Mar 31, 2009 | Mar | DISC |
| >A> | | @ | BASE/ML) | A 090029 | 001 | Mar 31, 2009 | Mar | DISC |
| >A> | | @ | EQ 1GM BASE/40ML (EQ 25MG | A 090029 | 001 | Mar 31, 2009 | Mar | DISC |
| | | | BASE/ML) | | | | | |

TABLET;ORAL

METHOTREXATE SODIUM

| | | | | | | | | |
|-----|----|-------|---------------|----------|-----|--------------|-----|------|
| >D> | AB | DAITO | EQ 2.5MG BASE | A 213362 | 001 | Aug 07, 2023 | Mar | DISC |
| >A> | | @ | EQ 2.5MG BASE | A 213362 | 001 | Aug 07, 2023 | Mar | DISC |

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

| | | | | | | | | |
|-----|--|----------------------|----------------------|----------|-----|--------------|-----|------|
| >A> | | ! ZYDUS LIFESCIENCES | 100MG/10ML (10MG/ML) | A 215636 | 004 | Mar 31, 2026 | Mar | NFTG |
|-----|--|----------------------|----------------------|----------|-----|--------------|-----|------|

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

| | | | | | | | | |
|-----|----|------------------|-------------------|----------|-----|--------------|-----|------|
| >D> | AB | MYLAN PHARMS INC | EQ 200MG TARTRATE | A 202033 | 004 | Dec 15, 2011 | Mar | DISC |
| >A> | | @ | EQ 200MG TARTRATE | A 202033 | 004 | Dec 15, 2011 | Mar | DISC |

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|---------------------|-------|----------|-----|--------------|-----|------|
| >A> | AB | MACLEODS PHARMS LTD | 150MG | A 219987 | 001 | Mar 23, 2026 | Mar | NEWA |
| >A> | AB | | 200MG | A 219987 | 002 | Mar 23, 2026 | Mar | NEWA |
| >A> | AB | | 250MG | A 219987 | 003 | Mar 23, 2026 | Mar | NEWA |

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

| | | | | | | | | |
|-----|----|--------|--------------------|----------|-----|--------------|-----|------|
| >A> | AP | ASPIRO | EQ 50MG BASE/VIAL | A 220296 | 001 | Mar 17, 2026 | Mar | NEWA |
| >A> | AP | | EQ 100MG BASE/VIAL | A 220296 | 002 | Mar 17, 2026 | Mar | NEWA |

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|---------------------|-------|----------|-----|--------------|-----|------|
| >D> | AB | THINQ PHARM-CRO PVT | 2.5MG | A 207613 | 001 | Nov 02, 2018 | Mar | CAHN |
| >D> | AB | | 5MG | A 207613 | 002 | Nov 02, 2018 | Mar | CAHN |
| >D> | AB | | 10MG | A 207613 | 003 | Nov 02, 2018 | Mar | CAHN |
| >A> | AB | UNIQUE | 2.5MG | A 207613 | 001 | Nov 02, 2018 | Mar | CAHN |
| >A> | AB | | 5MG | A 207613 | 002 | Nov 02, 2018 | Mar | CAHN |
| >A> | AB | | 10MG | A 207613 | 003 | Nov 02, 2018 | Mar | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

MIGLITOL

TABLET; ORAL

MIGLITOL

| | | | | | | | | |
|-----|---|--------------------|-------|---------|-----|--------------|-----|------|
| >A> | ! | ORIENT PHARMA | 25MG | A203965 | 001 | Feb 24, 2015 | Mar | CAHN |
| >A> | | | 50MG | A203965 | 002 | Feb 24, 2015 | Mar | CAHN |
| >A> | | | 100MG | A203965 | 003 | Feb 24, 2015 | Mar | CAHN |
| >D> | ! | WESTMINSTER PHARMS | 25MG | A203965 | 001 | Feb 24, 2015 | Mar | CAHN |
| >D> | | | 50MG | A203965 | 002 | Feb 24, 2015 | Mar | CAHN |
| >D> | | | 100MG | A203965 | 003 | Feb 24, 2015 | Mar | CAHN |

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

| | | | | | | | | |
|-----|----|-------|----------------|---------|-----|--------------|-----|------|
| >D> | AP | HIKMA | EQ 1MG BASE/ML | A075530 | 001 | May 28, 2002 | Mar | DISC |
| >A> | | @ | EQ 1MG BASE/ML | A075530 | 001 | May 28, 2002 | Mar | DISC |

MOMETASONE FUROATE

IMPLANT; IMPLANTATION

SINUVA

| | | | | | | | | |
|-----|--|---------------------|--------|---------|-----|--------------|-----|------|
| >D> | | + INTERSECT ENT INC | 1.35MG | N209310 | 001 | Dec 08, 2017 | Mar | CHRS |
| >A> | | + | 1.35MG | N209310 | 001 | Dec 08, 2017 | Mar | CHRS |

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

| | | | | | | | | |
|-----|----|---------------|-------------|---------|-----|--------------|-----|------|
| >D> | AB | AMNEAL PHARMS | EQ 4MG BASE | A205107 | 001 | Sep 04, 2020 | Mar | DISC |
| >A> | | @ | EQ 4MG BASE | A205107 | 001 | Sep 04, 2020 | Mar | DISC |
| >D> | AB | | EQ 5MG BASE | A205107 | 002 | Sep 04, 2020 | Mar | DISC |
| >A> | | @ | EQ 5MG BASE | A205107 | 002 | Sep 04, 2020 | Mar | DISC |

MORPHINE SULFATE

SOLUTION; ORAL

MORPHINE SULFATE

| | | | | | | | | |
|-----|----|-----------------|-----------|---------|-----|--------------|-----|------|
| >D> | AA | PADAGIS US | 100MG/5ML | A201574 | 001 | Aug 06, 2012 | Mar | DISC |
| >A> | | @ | 100MG/5ML | A201574 | 001 | Aug 06, 2012 | Mar | DISC |
| >D> | AA | TRIS PHARMA INC | 10MG/5ML | A203518 | 001 | May 12, 2015 | Mar | DISC |
| >A> | | @ | 10MG/5ML | A203518 | 001 | May 12, 2015 | Mar | DISC |

MUPIROCIN

OINTMENT; TOPICAL

CENTANY

| | | | | | | | | |
|-----|----|------------|----|---------|-----|--------------|-----|------|
| >D> | BX | PADAGIS US | 2% | N050788 | 001 | Dec 04, 2002 | Mar | DISC |
| >A> | | @ | 2% | N050788 | 001 | Dec 04, 2002 | Mar | DISC |

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLATE SODIUM

| | | | | | | | | |
|-----|----|------------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | TWI PHARMS | EQ 180MG BASE | A214289 | 001 | Nov 03, 2021 | Mar | DISC |
| >A> | | @ | EQ 180MG BASE | A214289 | 001 | Nov 03, 2021 | Mar | DISC |
| >D> | AB | | EQ 360MG BASE | A214289 | 002 | Nov 03, 2021 | Mar | DISC |
| >A> | | @ | EQ 360MG BASE | A214289 | 002 | Nov 03, 2021 | Mar | DISC |

NAFTIFINE HYDROCHLORIDE

GEL; TOPICAL

NAFTIFINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------|----|---------|-----|--------------|-----|------|
| >D> | AB | AMNEAL | 1% | A206165 | 001 | Mar 20, 2019 | Mar | DISC |
| >A> | | @ | 1% | A206165 | 001 | Mar 20, 2019 | Mar | DISC |
| >D> | AB | + | 1% | N019356 | 001 | Jun 18, 1990 | Mar | CTEC |
| >A> | | + | 1% | N019356 | 001 | Jun 18, 1990 | Mar | CTEC |

NAPROXEN

SUSPENSION; ORAL

NAPROXEN

| | | | | | | | | |
|-----|----|------------------|---------|---------|-----|--------------|-----|------|
| >D> | AB | AUROBINDO PHARMA | 25MG/ML | A216504 | 001 | Oct 03, 2025 | Mar | DISC |
| >A> | | @ | 25MG/ML | A216504 | 001 | Oct 03, 2025 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

| | | | | | | | | |
|-----|----|------------|---------------|----------|-----|--------------|-----|------|
| >D> | AB | PADAGIS US | EQ 1MG BASE | A 091326 | 001 | Jul 08, 2010 | Mar | DISC |
| >A> | | @ | EQ 1MG BASE | A 091326 | 001 | Jul 08, 2010 | Mar | DISC |
| >D> | AB | | EQ 2.5MG BASE | A 091326 | 002 | Jul 08, 2010 | Mar | DISC |
| >A> | | @ | EQ 2.5MG BASE | A 091326 | 002 | Jul 08, 2010 | Mar | DISC |

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

| | | | | | | | | |
|-----|----|---------|---------------|----------|-----|--------------|-----|------|
| >D> | AB | TORRENT | EQ 2.5MG BASE | A 203966 | 001 | Mar 02, 2018 | Mar | DISC |
| >A> | | @ | EQ 2.5MG BASE | A 203966 | 001 | Mar 02, 2018 | Mar | DISC |
| >D> | AB | | EQ 5MG BASE | A 203966 | 002 | Mar 02, 2018 | Mar | DISC |
| >A> | | @ | EQ 5MG BASE | A 203966 | 002 | Mar 02, 2018 | Mar | DISC |
| >D> | AB | | EQ 10MG BASE | A 203966 | 003 | Mar 02, 2018 | Mar | DISC |
| >A> | | @ | EQ 10MG BASE | A 203966 | 003 | Mar 02, 2018 | Mar | DISC |
| >D> | AB | | EQ 20MG BASE | A 203966 | 004 | Mar 02, 2018 | Mar | DISC |
| >A> | | @ | EQ 20MG BASE | A 203966 | 004 | Mar 02, 2018 | Mar | DISC |

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

| | | | | | | | | |
|-----|----|--------------------|---------------------|----------|-----|--------------|-----|------|
| >D> | AP | HIKMA | 3MG/3ML (1MG/ML) | A 216206 | 001 | Jul 13, 2022 | Mar | DISC |
| >A> | | @ | 3MG/3ML (1MG/ML) | A 216206 | 001 | Jul 13, 2022 | Mar | DISC |
| >A> | AP | NIVAGEN PHARMS INC | 5MG/10ML (0.5MG/ML) | A 212627 | 001 | Nov 03, 2022 | Mar | CAHN |
| >A> | AP | | 10MG/10ML (1MG/ML) | A 212627 | 002 | Nov 03, 2022 | Mar | CAHN |
| >D> | AP | UMEDICA | 5MG/10ML (0.5MG/ML) | A 212627 | 001 | Nov 03, 2022 | Mar | CAHN |
| >D> | AP | | 10MG/10ML (1MG/ML) | A 212627 | 002 | Nov 03, 2022 | Mar | CAHN |

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------|------|----------|-----|--------------|-----|------|
| >D> | AB | NAVINTA LLC | 20MG | A 218638 | 001 | Jun 25, 2025 | Mar | DISC |
| >A> | | @ | 20MG | A 218638 | 001 | Jun 25, 2025 | Mar | DISC |
| >D> | AB | | 30MG | A 218638 | 002 | Jun 25, 2025 | Mar | DISC |
| >A> | | @ | 30MG | A 218638 | 002 | Jun 25, 2025 | Mar | DISC |

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

| | | | | | | | | |
|-----|----|------------------------|------|----------|-----|--------------|-----|------|
| >D> | AB | HERITAGE PHARMA | 10MG | A 202644 | 001 | Apr 25, 2013 | Mar | CHRS |
| >A> | AB | ! | 10MG | A 202644 | 001 | Apr 25, 2013 | Mar | CHRS |
| >D> | AB | PROCARDIA +! PFIZER | 10MG | N 018482 | 001 | Dec 31, 1981 | Mar | DISC |
| >A> | | + @ | 10MG | N 018482 | 001 | Dec 31, 1981 | Mar | DISC |

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

| | | | | | | | | |
|-----|--|---------------|------|----------|-----|--------------|-----|------|
| >A> | | @ PHARMADAX | 30MG | A 216019 | 001 | Nov 18, 2022 | Mar | CAHN |
| >A> | | @ | 60MG | A 216019 | 002 | Nov 18, 2022 | Mar | CAHN |
| >D> | | @ SWISS PHARM | 30MG | A 216019 | 001 | Nov 18, 2022 | Mar | CAHN |
| >D> | | @ | 60MG | A 216019 | 002 | Nov 18, 2022 | Mar | CAHN |

NINTEDANIB ESYLATE

CAPSULE; ORAL

NINTEDANIB ESYLATE

| | | | | | | | | |
|-----|----|------------------------|---------------|----------|-----|--------------|-----|------|
| >A> | | | | | | | | |
| >A> | AB | APOTEX | EQ 100MG BASE | A 219227 | 001 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | | EQ 150MG BASE | A 219227 | 002 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | CIPLA | EQ 100MG BASE | A 212609 | 001 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | | EQ 150MG BASE | A 212609 | 002 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | DEXCEL | EQ 100MG BASE | A 219819 | 001 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | | EQ 150MG BASE | A 219819 | 002 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | DR REDDYS | EQ 100MG BASE | A 219283 | 001 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | | EQ 150MG BASE | A 219283 | 002 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | SANDOZ | EQ 100MG BASE | A 216915 | 001 | Apr 02, 2026 | Mar | NFTG |
| >A> | AB | | EQ 150MG BASE | A 216915 | 002 | Apr 02, 2026 | Mar | NFTG |
| >D> | | + BOEHRINGER INGELHEIM | EQ 100MG BASE | N 205832 | 001 | Oct 15, 2014 | Mar | CFTG |
| >A> | AB | + | EQ 100MG BASE | N 205832 | 001 | Oct 15, 2014 | Mar | CFTG |
| >D> | | +! | EQ 150MG BASE | N 205832 | 002 | Oct 15, 2014 | Mar | CFTG |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

NINTEDANIB ESYLATE

CAPSULE; ORAL

OFEV

>A> AB +! EQ 150MG BASE N205832 002 Oct 15, 2014 Mar CFTG

NIROGACESTAT HYDROBROMIDE

TABLET; ORAL

OGSIVEO

>D> + SPRINGWORKS EQ 50MG BASE N217677 001 Nov 27, 2023 Mar DISC

>A> + @ EQ 50MG BASE N217677 001 Nov 27, 2023 Mar DISC

NITRIC OXIDE

GAS; INHALATION

NOXIVENT

>D> @ LINDE GAS EQUIP 100PPM A207141 001 Oct 02, 2018 Mar CAHN

>D> AA 800PPM A207141 002 Oct 02, 2018 Mar CAHN

>A> @ VERO BIOTECH INC 100PPM A207141 001 Oct 02, 2018 Mar CAHN

>A> AA 800PPM A207141 002 Oct 02, 2018 Mar CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A> AB CREEKWOOD PHARMS 75MG;25MG A220269 001 Apr 07, 2026 Mar NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL

NITROGLYCERIN

>D> AB COSETTE 0.4% A216103 001 Feb 16, 2024 Mar CHRS

>A> AB ! 0.4% A216103 001 Feb 16, 2024 Mar CHRS

>D> RECTIV

>D> AB +! ABBVIE 0.4% N021359 001 Jun 21, 2011 Mar DISC

>A> + @ 0.4% N021359 001 Jun 21, 2011 Mar DISC

NOREPINEPHRINE BITARTRATE

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

>D> +! BAXTER HLTHCARE CORP EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) N214313 003 Nov 21, 2023 Mar CFTG

>A> AP +! EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) N214313 003 Nov 21, 2023 Mar CFTG

>A> AP SAGENT EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) A220483 001 Mar 26, 2026 Mar NFTG

NYSTATIN

SUSPENSION; ORAL

NILSTAT

>D> + @ CHARTWELL MOLECULES 100,000 UNITS/ML N050299 001 Apr 14, 1971 Mar CMFD

>A> AA + 100,000 UNITS/ML N050299 001 Apr 14, 1971 Mar CMFD

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

>A> AT MICRO LABS 0.3% A218557 001 Apr 08, 2026 Mar NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

>D> @ DASH PHARMS 6MG/ML A091540 001 Sep 29, 2011 Mar CAHN

>A> @ NATCO PHARMA USA 6MG/ML A091540 001 Sep 29, 2011 Mar CAHN

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

>D> @ AJANTA PHARMA LTD 3MG A218514 002 Jun 26, 2024 Mar CMFD

>A> AB 3MG A218514 002 Jun 26, 2024 Mar CMFD

>D> @ 6MG A218514 003 Jun 26, 2024 Mar CMFD

>A> AB 6MG A218514 003 Jun 26, 2024 Mar CMFD

>D> @ 9MG A218514 004 Jun 26, 2024 Mar CMFD

>A> AB 9MG A218514 004 Jun 26, 2024 Mar CMFD

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

| | | | | | | | | |
|-----|---|----------------|--------------------------------|---------|-----|--------------|-----|------|
| >D> | + | JANSSEN PHARMS | 39MG/0.25ML (39MG/0.25ML) | N022264 | 001 | Jul 31, 2009 | Mar | CHRS |
| >A> | + | ! | 39MG/0.25ML (39MG/0.25ML) | N022264 | 001 | Jul 31, 2009 | Mar | CHRS |
| >D> | + | | 78MG/0.5ML (78MG/0.5ML) | N022264 | 002 | Jul 31, 2009 | Mar | CHRS |
| >A> | + | ! | 78MG/0.5ML (78MG/0.5ML) | N022264 | 002 | Jul 31, 2009 | Mar | CHRS |
| >D> | + | | 117MG/0.75ML (117MG/0.75ML) | N022264 | 003 | Jul 31, 2009 | Mar | CHRS |
| >A> | + | ! | 117MG/0.75ML (117MG/0.75ML) | N022264 | 003 | Jul 31, 2009 | Mar | CHRS |
| >D> | + | | 234MG/1.5ML (156MG/ML) | N022264 | 005 | Jul 31, 2009 | Mar | CHRS |
| >A> | + | ! | 234MG/1.5ML (156MG/ML) | N022264 | 005 | Jul 31, 2009 | Mar | CHRS |

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|---------|----------------|---------|-----|--------------|-----|------|
| >A> | AB | ALEMBIC | EQ 12.5MG BASE | A217280 | 003 | Mar 26, 2026 | Mar | NEWA |
|-----|----|---------|----------------|---------|-----|--------------|-----|------|

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

| | | | | | | | | |
|-----|-----|----------------------|----------------------|---------|-----|--------------|-----|------|
| >A> | AP1 | BAXTER HLTHCARE CORP | 10MG/ML (10MG/ML) | A217032 | 001 | Apr 03, 2026 | Mar | NEWA |
| >A> | AP1 | | 50MG/5ML (10MG/ML) | A217032 | 002 | Apr 03, 2026 | Mar | NEWA |
| >A> | AP1 | | 100MG/10ML (10MG/ML) | A217032 | 003 | Apr 03, 2026 | Mar | NEWA |

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

| | | | | | | | | |
|-----|-----|----------------------|-----------|---------|-----|--------------|-----|------|
| >D> | AB | ALEMBIC | 1MG/0.5ML | A216444 | 001 | Sep 08, 2025 | Mar | CTEC |
| >A> | AB1 | | 1MG/0.5ML | A216444 | 001 | Sep 08, 2025 | Mar | CTEC |
| >D> | AB | AMNEAL | 1MG/0.5ML | A216601 | 001 | Nov 04, 2025 | Mar | CTEC |
| >A> | AB1 | | 1MG/0.5ML | A216601 | 001 | Nov 04, 2025 | Mar | CTEC |
| >D> | AB | BAXTER HLTHCARE CORP | 1MG/0.5ML | A216852 | 001 | Feb 26, 2026 | Mar | CTEC |
| >A> | AB2 | | 1MG/0.5ML | A216852 | 001 | Feb 26, 2026 | Mar | CTEC |
| >D> | | ! CIPLA | 1MG/0.5ML | A214596 | 001 | Apr 22, 2022 | Mar | CTEC |
| >A> | AB2 | ! | 1MG/0.5ML | A214596 | 001 | Apr 22, 2022 | Mar | CTEC |
| >D> | AB | | 1MG/0.5ML | A214966 | 001 | Jan 03, 2025 | Mar | CTEC |
| >A> | AB1 | | 1MG/0.5ML | A214966 | 001 | Jan 03, 2025 | Mar | CTEC |
| >D> | AB | ! INTL MEDICATION | 1MG/0.5ML | A083722 | 001 | Mar 01, 1976 | Mar | CTEC |
| >A> | AB1 | ! | 1MG/0.5ML | A083722 | 001 | Mar 01, 1976 | Mar | CTEC |
| >A> | AB | ORBICULAR | 1MG/0.5ML | A216298 | 001 | Mar 13, 2026 | Mar | NEWA |
| >A> | AB1 | | 1MG/0.5ML | A216298 | 001 | Mar 13, 2026 | Mar | CTEC |

>A> PIFLUFOLASTAT F-18

>A> SOLUTION;INTRAVENOUS

>A> PYLARIFY TRUVU

| | | | | | | | | |
|-----|---|----------|-------------------|---------|-----|--------------|-----|------|
| >A> | + | APHELION | 1mCi/mL-120mCi/mL | N220089 | 001 | Mar 06, 2026 | Mar | NEWA |
|-----|---|----------|-------------------|---------|-----|--------------|-----|------|

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|------------|-----|---------|-----|--------------|-----|------|
| >D> | AB | PADAGIS US | 5MG | A076746 | 001 | Nov 16, 2004 | Mar | DISC |
| >A> | | @ | 5MG | A076746 | 001 | Nov 16, 2004 | Mar | DISC |

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

| | | | | | | | | |
|-----|----|---------------------|----------------------|---------|-----|--------------|-----|------|
| >D> | AP | TEVA PHARMS USA INC | 24MG/1.2ML (20MG/ML) | A205197 | 001 | Jul 24, 2023 | Mar | DISC |
| >A> | | @ | 24MG/1.2ML (20MG/ML) | A205197 | 001 | Jul 24, 2023 | Mar | DISC |

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

| | | | | | | | | |
|-----|----|------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | PADAGIS US | 8MEQ | A200185 | 001 | May 18, 2011 | Mar | DISC |
| >A> | | @ | 8MEQ | A200185 | 001 | May 18, 2011 | Mar | DISC |
| >D> | AB | | 10MEQ | A200185 | 002 | May 18, 2011 | Mar | DISC |
| >A> | | @ | 10MEQ | A200185 | 002 | May 18, 2011 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

| | | | | | | | | | |
|-----|---|---|-----------------|--------------|---------|-----|--------------|-----|------|
| >D> | + | ! | BAXTER HLTHCARE | 2.24GM/100ML | N019904 | 003 | Dec 26, 1989 | Mar | DISC |
| >A> | + | @ | | 2.24GM/100ML | N019904 | 003 | Dec 26, 1989 | Mar | DISC |

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS

POTASSIUM PHOSPHATES

| | | | | | | | | | |
|-----|----|--|--------|--|---------|-----|--------------|-----|------|
| >A> | AP | | CAPLIN | 1.18GM/5ML (236MG/ML); 1.12GM/5ML | A220373 | 001 | Mar 12, 2026 | Mar | NEWA |
| >A> | AP | | | 3.54GM/15ML (236MG/ML); 3.36GM/15ML | A220373 | 002 | Mar 12, 2026 | Mar | NEWA |
| >A> | AP | | | 11.8GM/50ML (236MG/ML); 11.2GM/50ML | A220373 | 003 | Mar 12, 2026 | Mar | NEWA |

PREGABALIN

SOLUTION; ORAL

PREGABALIN

| | | | | | | | | | |
|-----|----|--|-----------------|---------|---------|-----|--------------|-----|------|
| >D> | AA | | ANDA REPOSITORY | 20MG/ML | A212604 | 001 | Feb 18, 2022 | Mar | CAHN |
| >A> | AA | | PATRIN | 20MG/ML | A212604 | 001 | Feb 18, 2022 | Mar | CAHN |

PROGESTERONE

INSERT; VAGINAL

PROGESTERONE

| | | | | | | | | | |
|-----|----|--|---------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | | GLENMARK PHARMS LTD | 100MG | A216363 | 001 | Apr 08, 2026 | Mar | NEWA |
|-----|----|--|---------------------|-------|---------|-----|--------------|-----|------|

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL

HEMANGEOL

| | | | | | | | | | | |
|-----|--|---|---|--------|-----------|---------|-----|--------------|-----|------|
| >A> | | + | ! | ETON | 4.28MG/ML | N205410 | 001 | Mar 14, 2014 | Mar | CAHN |
| >D> | | + | ! | PIERRE | 4.28MG/ML | N205410 | 001 | Mar 14, 2014 | Mar | CAHN |

RAMELTEON

TABLET; ORAL

RAMELTEON

| | | | | | | | | | |
|-----|----|--|---------|-----|---------|-----|--------------|-----|------|
| >D> | BX | | XIROMED | 8MG | A216209 | 001 | Nov 25, 2022 | Mar | CTEC |
| >A> | AB | | | 8MG | A216209 | 001 | Nov 25, 2022 | Mar | CTEC |

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | | | | |
|-----|--|---|---------------|---------------|---------|-----|--------------|-----|------|
| >D> | | @ | PHARMOBEDIANT | EQ 150MG BASE | A075564 | 001 | Oct 27, 2000 | Mar | CAHN |
| >D> | | @ | | EQ 300MG BASE | A075564 | 002 | Oct 27, 2000 | Mar | CAHN |
| >A> | | @ | RISING | EQ 150MG BASE | A075564 | 001 | Oct 27, 2000 | Mar | CAHN |
| >A> | | @ | | EQ 300MG BASE | A075564 | 002 | Oct 27, 2000 | Mar | CAHN |

| | | | | | | | | | | |
|-----|--|---|---|----------------|-------------|---------|-----|--------------|-----|------|
| >A> | | | | | | | | | | |
| >A> | | | | | | | | | | |
| >A> | | | | | | | | | | |
| >A> | | + | ! | CORCEPT THERAP | 100MG; 25MG | N220641 | 001 | Mar 25, 2026 | Mar | NEWA |

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

| | | | | | | | | | |
|-----|----|---|------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | | PADAGIS US | 0.5MG | A201189 | 001 | Jul 17, 2013 | Mar | DISC |
| >A> | | @ | | 0.5MG | A201189 | 001 | Jul 17, 2013 | Mar | DISC |
| >D> | AB | | | 1MG | A201189 | 002 | Jan 22, 2014 | Mar | DISC |
| >A> | | @ | | 1MG | A201189 | 002 | Jan 22, 2014 | Mar | DISC |
| >D> | AB | | | 2MG | A201189 | 003 | Jan 22, 2014 | Mar | DISC |
| >A> | | @ | | 2MG | A201189 | 003 | Jan 22, 2014 | Mar | DISC |

RIBAVIRIN

FOR SOLUTION; INHALATION

RIBAVIRIN

| | | | | | | | | | |
|-----|--|---|-------------|----------|---------|-----|--------------|-----|------|
| >D> | | ! | NAVINTA LLC | 6GM/VIAL | A207366 | 001 | Oct 06, 2016 | Mar | DISC |
| >A> | | @ | | 6GM/VIAL | A207366 | 001 | Oct 06, 2016 | Mar | DISC |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

RIFABUTIN

CAPSULE;ORAL

RIFABUTIN

| | | | | | | | | |
|-----|----|-----------|-------|---------|-----|--------------|-----|------|
| >A> | AB | I3 PHARMS | 150MG | A212430 | 001 | Mar 19, 2026 | Mar | NEWA |
|-----|----|-----------|-------|---------|-----|--------------|-----|------|

RIFAXIMIN

TABLET;ORAL

RIFAXIMIN

| | | | | | | | | |
|-----|----|---------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | ACTAVIS LABS FL INC | 550MG | A208959 | 001 | Mar 19, 2026 | Mar | NFTG |
|-----|----|---------------------|-------|---------|-----|--------------|-----|------|

XIFAXAN

| | | | | | | | | |
|-----|--|----------------|-------|---------|-----|--------------|-----|------|
| >D> | | ! SALIX PHARMS | 550MG | N021361 | 002 | Mar 24, 2010 | Mar | CFTG |
|-----|--|----------------|-------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|----|---|-------|---------|-----|--------------|-----|------|
| >A> | AB | ! | 550MG | N021361 | 002 | Mar 24, 2010 | Mar | CFTG |
|-----|----|---|-------|---------|-----|--------------|-----|------|

RILUZOLE

TABLET;ORAL

RILUTEK

| | | | | | | | | |
|-----|--|-------------|------|---------|-----|--------------|-----|------|
| >A> | | + @ AZURITY | 50MG | N020599 | 001 | Dec 12, 1995 | Mar | CAHN |
|-----|--|-------------|------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|-----------|------|---------|-----|--------------|-----|------|
| >D> | | + @ COVIS | 50MG | N020599 | 001 | Dec 12, 1995 | Mar | CAHN |
|-----|--|-----------|------|---------|-----|--------------|-----|------|

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

| | | | | | | | | |
|-----|--|---------------|--------|---------|-----|--------------|-----|------|
| >D> | | @ DASH PHARMS | 0.25MG | A091537 | 006 | Feb 12, 2013 | Mar | CAHN |
|-----|--|---------------|--------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-------|---------|-----|--------------|-----|------|
| >D> | | @ | 0.5MG | A091537 | 001 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 1MG | A091537 | 002 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 2MG | A091537 | 003 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 3MG | A091537 | 004 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 4MG | A091537 | 005 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|--------------------|--------|---------|-----|--------------|-----|------|
| >A> | | @ NATCO PHARMA USA | 0.25MG | A091537 | 006 | Feb 12, 2013 | Mar | CAHN |
|-----|--|--------------------|--------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-------|---------|-----|--------------|-----|------|
| >A> | | @ | 0.5MG | A091537 | 001 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 1MG | A091537 | 002 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 2MG | A091537 | 003 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 3MG | A091537 | 004 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 4MG | A091537 | 005 | Mar 30, 2011 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

TABLET;ORAL

RISPERIDONE

| | | | | | | | | |
|-----|--|---------------|--------|---------|-----|--------------|-----|------|
| >D> | | @ DASH PHARMS | 0.25MG | A076288 | 001 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---------------|--------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-------|---------|-----|--------------|-----|------|
| >D> | | @ | 0.5MG | A076288 | 002 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 1MG | A076288 | 003 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 2MG | A076288 | 004 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 3MG | A076288 | 005 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >D> | | @ | 4MG | A076288 | 006 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|--------------------|--------|---------|-----|--------------|-----|------|
| >A> | | @ NATCO PHARMA USA | 0.25MG | A076288 | 001 | Sep 15, 2008 | Mar | CAHN |
|-----|--|--------------------|--------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-------|---------|-----|--------------|-----|------|
| >A> | | @ | 0.5MG | A076288 | 002 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 1MG | A076288 | 003 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 2MG | A076288 | 004 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 3MG | A076288 | 005 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-----|---------|-----|--------------|-----|------|
| >A> | | @ | 4MG | A076288 | 006 | Sep 15, 2008 | Mar | CAHN |
|-----|--|---|-----|---------|-----|--------------|-----|------|

RITONAVIR

TABLET;ORAL

RITONAVIR

| | | | | | | | | |
|-----|----|--------|-------|---------|-----|--------------|-----|------|
| >D> | AB | AMNEAL | 100MG | A208890 | 001 | Sep 17, 2018 | Mar | DISC |
|-----|----|--------|-------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|-------|---------|-----|--------------|-----|------|
| >A> | | @ | 100MG | A208890 | 001 | Sep 17, 2018 | Mar | DISC |
|-----|--|---|-------|---------|-----|--------------|-----|------|

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

| | | | | | | | | |
|-----|--|--------|-------------|---------|-----|--------------|-----|------|
| >A> | | @ ANVI | EQ 5MG BASE | A079161 | 001 | Jul 19, 2016 | Mar | CAHN |
|-----|--|--------|-------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|--------------|---------|-----|--------------|-----|------|
| >A> | | @ | EQ 10MG BASE | A079161 | 002 | Jul 19, 2016 | Mar | CAHN |
|-----|--|---|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|--------------|---------|-----|--------------|-----|------|
| >A> | | @ | EQ 20MG BASE | A079161 | 003 | Jul 19, 2016 | Mar | CAHN |
|-----|--|---|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|--------------|---------|-----|--------------|-----|------|
| >A> | | @ | EQ 40MG BASE | A079161 | 004 | Jul 19, 2016 | Mar | CAHN |
|-----|--|---|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|------------------|-------------|---------|-----|--------------|-----|------|
| >D> | | @ STRIDES PHARMA | EQ 5MG BASE | A079161 | 001 | Jul 19, 2016 | Mar | CAHN |
|-----|--|------------------|-------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|--------------|---------|-----|--------------|-----|------|
| >D> | | @ | EQ 10MG BASE | A079161 | 002 | Jul 19, 2016 | Mar | CAHN |
|-----|--|---|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|--------------|---------|-----|--------------|-----|------|
| >D> | | @ | EQ 20MG BASE | A079161 | 003 | Jul 19, 2016 | Mar | CAHN |
|-----|--|---|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|--|---|--------------|---------|-----|--------------|-----|------|
| >D> | | @ | EQ 40MG BASE | A079161 | 004 | Jul 19, 2016 | Mar | CAHN |
|-----|--|---|--------------|---------|-----|--------------|-----|------|

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

| | | | | | | | | | |
|-----|-----------|----------------|---------|-----|--------------|-----|------|--|--|
| >A> | WEGOVY HD | | | | | | | | |
| >A> | +! NOVO | 7.2MG/0.75ML | N215256 | 006 | Mar 19, 2026 | Mar | NEWA | | |
| | | (7.2MG/0.75ML) | | | | | | | |

TABLET;ORAL

| | | | | | | | | | |
|-----|----------|-------|---------|-----|--------------|-----|------|--|--|
| >A> | OZEMPIC | | | | | | | | |
| >A> | +! NOVO | 1.5MG | N213051 | 004 | Dec 09, 2024 | Mar | CTNA | | |
| >A> | +! | 4MG | N213051 | 005 | Dec 09, 2024 | Mar | CTNA | | |
| >A> | +! | 9MG | N213051 | 006 | Dec 09, 2024 | Mar | CTNA | | |
| >D> | RYBELSUS | | | | | | | | |
| >D> | +! NOVO | 1.5MG | N213051 | 004 | Dec 09, 2024 | Mar | CTNA | | |
| >D> | +! | 4MG | N213051 | 005 | Dec 09, 2024 | Mar | CTNA | | |
| >D> | +! | 9MG | N213051 | 006 | Dec 09, 2024 | Mar | CTNA | | |
| | WEGOVY | | | | | | | | |
| >D> | + NOVO | 1.5MG | N218316 | 001 | Dec 22, 2025 | Mar | CHRS | | |
| >A> | +! | 1.5MG | N218316 | 001 | Dec 22, 2025 | Mar | CHRS | | |
| >D> | + | 4MG | N218316 | 002 | Dec 22, 2025 | Mar | CHRS | | |
| >A> | +! | 4MG | N218316 | 002 | Dec 22, 2025 | Mar | CHRS | | |
| >D> | + | 9MG | N218316 | 003 | Dec 22, 2025 | Mar | CHRS | | |
| >A> | +! | 9MG | N218316 | 003 | Dec 22, 2025 | Mar | CHRS | | |

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL

SERTRALINE HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|------------|---------------|---------|-----|--------------|-----|------|--|
| >A> | AB | AMNEAL | EQ 150MG BASE | A219655 | 001 | Jan 28, 2026 | Mar | CAHN | |
| >A> | AB | | EQ 200MG BASE | A219655 | 002 | Jan 28, 2026 | Mar | CAHN | |
| >D> | AB | SKG PHARMA | EQ 150MG BASE | A219655 | 001 | Jan 28, 2026 | Mar | CAHN | |
| >D> | AB | | EQ 200MG BASE | A219655 | 002 | Jan 28, 2026 | Mar | CAHN | |

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

| | | | | | | | | | |
|-----|----|----------------------|-----------------|---------|-----|--------------|-----|------|--|
| >D> | AB | +! VIATRIS | EQ 10MG BASE/ML | N203109 | 001 | Aug 30, 2012 | Mar | DISC | |
| >A> | | + @ | EQ 10MG BASE/ML | N203109 | 001 | Aug 30, 2012 | Mar | DISC | |
| | | SILDENAFIL CITRATE | | | | | | | |
| >D> | AB | AUROBINDO PHARMA LTD | EQ 10MG BASE/ML | A214773 | 001 | Dec 23, 2022 | Mar | CHRS | |
| >A> | AB | ! | EQ 10MG BASE/ML | A214773 | 001 | Dec 23, 2022 | Mar | CHRS | |

SIPONIMOD

TABLET;ORAL

MAYZENT

| | | | | | | | | | |
|-----|----|------------|----------------|---------|-----|--------------|-----|------|--|
| >D> | AB | + NOVARTIS | EQ 0.25MG BASE | N209884 | 001 | Mar 26, 2019 | Mar | CTEC | |
| >A> | | + | EQ 0.25MG BASE | N209884 | 001 | Mar 26, 2019 | Mar | CTEC | |
| >D> | AB | + | EQ 1MG BASE | N209884 | 003 | Aug 24, 2021 | Mar | CTEC | |
| >A> | | + | EQ 1MG BASE | N209884 | 003 | Aug 24, 2021 | Mar | CTEC | |
| >D> | AB | +! | EQ 2MG BASE | N209884 | 002 | Mar 26, 2019 | Mar | CTEC | |
| >A> | | +! | EQ 2MG BASE | N209884 | 002 | Mar 26, 2019 | Mar | CTEC | |

SIPONIMOD

| | | | | | | | | | |
|-----|----|----------------------|----------------|---------|-----|--------------|-----|------|--|
| >D> | AB | AUROBINDO PHARMA LTD | EQ 0.25MG BASE | A218459 | 001 | Mar 06, 2026 | Mar | DISC | |
| >A> | | @ | EQ 0.25MG BASE | A218459 | 001 | Mar 06, 2026 | Mar | DISC | |
| >D> | AB | | EQ 1MG BASE | A218459 | 002 | Mar 06, 2026 | Mar | DISC | |
| >A> | | @ | EQ 1MG BASE | A218459 | 002 | Mar 06, 2026 | Mar | DISC | |
| >D> | AB | | EQ 2MG BASE | A218459 | 003 | Mar 06, 2026 | Mar | DISC | |
| >A> | | @ | EQ 2MG BASE | A218459 | 003 | Mar 06, 2026 | Mar | DISC | |

SUCCINYLCHOLINE CHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

| | | | | | | | | | |
|-----|----|--------------------|---------------------|---------|-----|--------------|-----|------|--|
| >D> | AP | FRESENIUS KABI USA | 100MG/5ML (20MG/ML) | A217884 | 001 | Feb 11, 2025 | Mar | CHRS | |
| >A> | AP | ! | 100MG/5ML (20MG/ML) | A217884 | 001 | Feb 11, 2025 | Mar | CHRS | |
| >D> | AP | +! HIKMA | 100MG/5ML (20MG/ML) | N215143 | 001 | Aug 20, 2021 | Mar | DISC | |
| >A> | | + @ | 100MG/5ML (20MG/ML) | N215143 | 001 | Aug 20, 2021 | Mar | DISC | |

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTANIL CITRATE

| | | | | | | | | | |
|-----|----|-------|-------------------|---------|-----|--------------|-----|------|--|
| >D> | AP | HIKMA | EQ 0.05MG BASE/ML | A074413 | 001 | Dec 15, 1995 | Mar | DISC | |
| >A> | | @ | EQ 0.05MG BASE/ML | A074413 | 001 | Dec 15, 1995 | Mar | DISC | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

| | | | | | | | | | |
|-----|--|----------------------|-----|----------|-----|--------------|-----|------|--|
| >D> | | SULFACETAMIDE SODIUM | | | | | | | |
| >D> | | ! PADAGIS US | 10% | A 080029 | 001 | Dec 22, 1971 | Mar | DISC | |
| >A> | | @ | 10% | A 080029 | 001 | Dec 22, 1971 | Mar | DISC | |

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

| | | | | | | | | | |
|-----|----|------------|----|----------|-----|--------------|-----|------|--|
| >D> | AB | PADAGIS US | 5% | A 211848 | 001 | Oct 13, 2020 | Mar | DISC | |
| >A> | | @ | 5% | A 211848 | 001 | Oct 13, 2020 | Mar | DISC | |

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

| | | | | | | | | | |
|-----|----|-----------------|----------|----------|-----|--------------|-----|------|--|
| >D> | AO | CAPLIN ONE LABS | 100MG/ML | A 040615 | 001 | Aug 10, 2006 | Mar | DISC | |
| >A> | | @ | 100MG/ML | A 040615 | 001 | Aug 10, 2006 | Mar | DISC | |
| >D> | AO | | 200MG/ML | A 040615 | 002 | Aug 10, 2006 | Mar | DISC | |
| >A> | | @ | 200MG/ML | A 040615 | 002 | Aug 10, 2006 | Mar | DISC | |

TICAGRELOR

TABLET;ORAL

TICAGRELOR

| | | | | | | | | | |
|-----|----|------------------|------|----------|-----|--------------|-----|------|--|
| >D> | AB | AMNEAL | 60MG | A 208531 | 002 | Oct 28, 2025 | Mar | DISC | |
| >A> | | @ | 60MG | A 208531 | 002 | Oct 28, 2025 | Mar | DISC | |
| >A> | AB | ZHEJIANG JINGXIN | 60MG | A 219006 | 001 | Mar 24, 2026 | Mar | NEWA | |
| >A> | AB | | 90MG | A 219006 | 002 | Mar 24, 2026 | Mar | NEWA | |

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

| | | | | | | | | | |
|-----|----|-----------------------|-----------|----------|-----|--------------|-----|------|--|
| >D> | AP | +! FRESENIUS KABI USA | 50MG/VIAL | N 205645 | 001 | Dec 01, 2016 | Mar | DISC | |
| >A> | | + @ | 50MG/VIAL | N 205645 | 001 | Dec 01, 2016 | Mar | DISC | |

TIMOLOL MALEATE

TABLET;ORAL

TIMOLOL MALEATE

| | | | | | | | | | |
|-----|----|--------|------|----------|-----|--------------|-----|------|--|
| >D> | AB | MYLAN | 5MG | A 072668 | 002 | Jun 08, 1990 | Mar | DISC | |
| >A> | | @ | 5MG | A 072668 | 002 | Jun 08, 1990 | Mar | DISC | |
| >D> | AB | ! | 20MG | A 072668 | 001 | Jun 08, 1990 | Mar | DISC | |
| >A> | | @ | 20MG | A 072668 | 001 | Jun 08, 1990 | Mar | DISC | |
| >D> | AB | RISING | 5MG | A 207556 | 001 | May 02, 2019 | Mar | CTEC | |
| >A> | | | 5MG | A 207556 | 001 | May 02, 2019 | Mar | CTEC | |
| >D> | AB | | 20MG | A 207556 | 003 | May 02, 2019 | Mar | CTEC | |
| >A> | | | 20MG | A 207556 | 003 | May 02, 2019 | Mar | CTEC | |
| >A> | | ! | 20MG | A 207556 | 003 | May 02, 2019 | Mar | CHRS | |

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

| | | | | | | | | | |
|-----|----|---------------------|-------|----------|-----|--------------|-----|------|--|
| >D> | AB | THINQ PHARM-CRO PVT | 250MG | A 202489 | 001 | Oct 09, 2013 | Mar | CAHN | |
| >D> | AB | | 500MG | A 202489 | 002 | Oct 09, 2013 | Mar | CAHN | |
| >A> | AB | UNIQUE | 250MG | A 202489 | 001 | Oct 09, 2013 | Mar | CAHN | |
| >A> | AB | | 500MG | A 202489 | 002 | Oct 09, 2013 | Mar | CAHN | |

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL

TIOPRONIN

| | | | | | | | | | |
|-----|----|--------|-------|----------|-----|--------------|-----|------|--|
| >D> | AB | AMNEAL | 100MG | A 216278 | 002 | Aug 29, 2025 | Mar | DISC | |
| >A> | | @ | 100MG | A 216278 | 002 | Aug 29, 2025 | Mar | DISC | |
| >D> | AB | | 300MG | A 216278 | 001 | Aug 15, 2023 | Mar | DISC | |
| >A> | | @ | 300MG | A 216278 | 001 | Aug 15, 2023 | Mar | DISC | |

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

ZANAFLEX

| | | | | | | | | | |
|-----|----|---------------------|-------------|----------|-----|--------------|-----|------|--|
| >D> | AB | + LEGACY PHARMA USA | EQ 4MG BASE | N 021447 | 002 | Aug 29, 2002 | Mar | CHRS | |
| >A> | AB | +! | EQ 4MG BASE | N 021447 | 002 | Aug 29, 2002 | Mar | CHRS | |
| >D> | AB | +! | EQ 6MG BASE | N 021447 | 003 | Aug 29, 2002 | Mar | CHRS | |
| >A> | AB | + | EQ 6MG BASE | N 021447 | 003 | Aug 29, 2002 | Mar | CHRS | |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

TOLCAPONE

TABLET; ORAL

TASMAR

| | | | | | | | | | |
|------------------|----|---|--------------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | + | BAUSCH | 100MG | N020697 | 001 | Jan 29, 1998 | Mar | CTEC |
| >A> | | + | | 100MG | N020697 | 001 | Jan 29, 1998 | Mar | CTEC |
| <u>TOLCAPONE</u> | | | | | | | | | |
| >D> | AB | | INGENUS PHARMS LLC | 100MG | A208937 | 001 | Aug 07, 2018 | Mar | DISC |
| >A> | | @ | | 100MG | A208937 | 001 | Aug 07, 2018 | Mar | DISC |

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

| | | | | | | | | | |
|-----|----|--|----------------|-----|---------|-----|--------------|-----|------|
| >D> | AB | | PTS CONSULTING | 1MG | A204721 | 001 | Jan 24, 2020 | Mar | CAHN |
| >D> | AB | | | 2MG | A204721 | 002 | Jan 24, 2020 | Mar | CAHN |
| >A> | AB | | UNIQUE | 1MG | A204721 | 001 | Jan 24, 2020 | Mar | CAHN |
| >A> | AB | | | 2MG | A204721 | 002 | Jan 24, 2020 | Mar | CAHN |

TOPOTECAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

| | | | | | | | | | |
|-----|--|---|------------------|-------------------------------------|---------|-----|--------------|-----|------|
| >D> | | @ | DASH PHARMS | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A206074 | 001 | Nov 24, 2017 | Mar | CAHN |
| >A> | | @ | NATCO PHARMA USA | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A206074 | 001 | Nov 24, 2017 | Mar | CAHN |

TRAMADOL HYDROCHLORIDE

SOLUTION; ORAL

QDOLO

| | | | | | | | | | |
|-----|--|---|------------|--------|---------|-----|--------------|-----|------|
| >D> | | + | @ ATHENA | 5MG/ML | N214044 | 001 | Sep 01, 2020 | Mar | CAHN |
| >A> | | + | @ ROSEMONT | 5MG/ML | N214044 | 001 | Sep 01, 2020 | Mar | CAHN |

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|--|------------------|------|---------|-----|--------------|-----|------|
| >A> | AB | | RUBICON | 25MG | A208708 | 003 | Nov 27, 2023 | Mar | CTEC |
| >D> | | | RUBICON RESEARCH | 25MG | A208708 | 003 | Nov 27, 2023 | Mar | CTEC |
| >A> | AB | | STRIDES PHARMA | 25MG | A202075 | 002 | Mar 23, 2026 | Mar | NEWA |

TRETINOIN

CREAM; TOPICAL

TRETINOIN

| | | | | | | | | | |
|-----|-----|--|--------|-------|---------|-----|--------------|-----|------|
| >A> | AB1 | | ENCUBE | 0.05% | A217832 | 001 | Mar 25, 2026 | Mar | NEWA |
|-----|-----|--|--------|-------|---------|-----|--------------|-----|------|

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALGANCICLOVIR HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|--|------------|---------|---------|-----|--------------|-----|------|
| >A> | AB | | MICRO LABS | 50MG/ML | A218838 | 001 | Mar 19, 2026 | Mar | NEWA |
|-----|----|--|------------|---------|---------|-----|--------------|-----|------|

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|---|--------------|---------------|---------|-----|--------------|-----|------|
| >D> | | @ | PAI HOLDINGS | EQ 125MG BASE | A065478 | 001 | Apr 09, 2012 | Mar | CMFD |
| >A> | AB | | | EQ 125MG BASE | A065478 | 001 | Apr 09, 2012 | Mar | CMFD |
| >D> | | @ | | EQ 250MG BASE | A065478 | 002 | Apr 09, 2012 | Mar | CMFD |
| >A> | AB | | | EQ 250MG BASE | A065478 | 002 | Apr 09, 2012 | Mar | CMFD |

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

| | | | | | | | | | |
|-----|----|---|--------------|-------------------------|---------|-----|--------------|-----|------|
| >D> | AP | | EAGLE PHARMS | 20UNITS/ML (20UNITS/ML) | A211538 | 001 | Dec 15, 2021 | Mar | DISC |
| >A> | | @ | | 20UNITS/ML (20UNITS/ML) | A211538 | 001 | Dec 15, 2021 | Mar | DISC |

VENLAFAXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|---|-------------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | | ADAPTIS | EQ 75MG BASE | A213927 | 001 | Jan 21, 2021 | Mar | DISC |
| >A> | | @ | | EQ 75MG BASE | A213927 | 001 | Jan 21, 2021 | Mar | DISC |
| >A> | | @ | PHARMADAX | EQ 75MG BASE | A214423 | 001 | Jan 04, 2022 | Mar | CAHN |
| >A> | | @ | | EQ 150MG BASE | A214423 | 002 | Jan 04, 2022 | Mar | CAHN |
| >D> | | @ | SWISS PHARM | EQ 75MG BASE | A214423 | 001 | Jan 04, 2022 | Mar | CAHN |
| >D> | | @ | | EQ 150MG BASE | A214423 | 002 | Jan 04, 2022 | Mar | CAHN |

ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------|---------------------|---------|-----|--------------|-----|------|
| >D> | AP | AMNEAL | 5MG/2ML (2.5MG/ML) | A210994 | 001 | Jul 13, 2018 | Mar | DISC |
| >A> | | @ | 5MG/2ML (2.5MG/ML) | A210994 | 001 | Jul 13, 2018 | Mar | DISC |
| >D> | AP | | 10MG/4ML (2.5MG/ML) | A210994 | 002 | Jul 13, 2018 | Mar | DISC |
| >A> | | @ | 10MG/4ML (2.5MG/ML) | A210994 | 002 | Jul 13, 2018 | Mar | DISC |

ADDITIONS/DELETIONS FOR OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

| | | | | | | | |
|---------------------------------------|------------------|------|----------|-----|--------------|-----|------|
| >D> | AMNEAL PHARMS NY | 5MG | A 078780 | 001 | Jan 21, 2010 | Mar | DISC |
| >A> | @ | 5MG | A 078780 | 001 | Jan 21, 2010 | Mar | DISC |
| >D> | | 10MG | A 078780 | 004 | Jan 21, 2010 | Mar | DISC |
| >A> | @ | 10MG | A 078780 | 004 | Jan 21, 2010 | Mar | DISC |
| CETIRIZINE HYDROCHLORIDE HIVES RELIEF | | | | | | | |
| >D> | AMNEAL PHARMS NY | 5MG | A 078780 | 003 | Jan 21, 2010 | Mar | DISC |
| >A> | @ | 5MG | A 078780 | 003 | Jan 21, 2010 | Mar | DISC |
| >D> | | 10MG | A 078780 | 002 | Jan 21, 2010 | Mar | DISC |
| >A> | @ | 10MG | A 078780 | 002 | Jan 21, 2010 | Mar | DISC |

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | |
|-----|------------------|------------|----------|-----|--------------|-----|------|
| >D> | AMNEAL PHARMS CO | 25MG;220MG | A 209726 | 001 | Oct 23, 2018 | Mar | DISC |
| >A> | @ | 25MG;220MG | A 209726 | 001 | Oct 23, 2018 | Mar | DISC |

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

| | | | | | | | |
|---|---------------|-------|----------|-----|--------------|-----|------|
| >D> | TEVA | 30MG | A 076447 | 004 | Apr 13, 2011 | Mar | DISC |
| >A> | @ | 30MG | A 076447 | 004 | Apr 13, 2011 | Mar | DISC |
| >A> | TIME CAP LABS | 30MG | A 079112 | 002 | Feb 08, 2012 | Mar | CAHN |
| >D> | WOCKHARDT | 30MG | A 079112 | 002 | Feb 08, 2012 | Mar | CAHN |
| CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES | | | | | | | |
| >D> | TEVA | 30MG | A 076447 | 005 | Apr 13, 2011 | Mar | DISC |
| >A> | @ | 30MG | A 076447 | 005 | Apr 13, 2011 | Mar | DISC |
| >A> | TIME CAP LABS | 30MG | A 079112 | 001 | Feb 08, 2012 | Mar | CAHN |
| >D> | WOCKHARDT | 30MG | A 079112 | 001 | Feb 08, 2012 | Mar | CAHN |
| FEXOFENADINE HYDROCHLORIDE ALLERGY | | | | | | | |
| >D> | RISING | 60MG | A 077081 | 006 | Jul 21, 2011 | Mar | DISC |
| >A> | @ | 60MG | A 077081 | 006 | Jul 21, 2011 | Mar | DISC |
| >D> | | 180MG | A 077081 | 008 | Jul 21, 2011 | Mar | DISC |
| >A> | @ | 180MG | A 077081 | 008 | Jul 21, 2011 | Mar | DISC |
| >D> | TEVA | 60MG | A 076447 | 006 | Apr 13, 2011 | Mar | DISC |
| >A> | @ | 60MG | A 076447 | 006 | Apr 13, 2011 | Mar | DISC |
| >D> | | 180MG | A 076447 | 008 | Apr 13, 2011 | Mar | DISC |
| >A> | @ | 180MG | A 076447 | 008 | Apr 13, 2011 | Mar | DISC |
| >A> | TIME CAP LABS | 60MG | A 079112 | 004 | Feb 08, 2012 | Mar | CAHN |
| >A> | | 180MG | A 079112 | 006 | Feb 08, 2012 | Mar | CAHN |
| >D> | WOCKHARDT | 60MG | A 079112 | 004 | Feb 08, 2012 | Mar | CAHN |
| >D> | | 180MG | A 079112 | 006 | Feb 08, 2012 | Mar | CAHN |
| FEXOFENADINE HYDROCHLORIDE HIVES | | | | | | | |
| >D> | RISING | 60MG | A 077081 | 007 | Jul 21, 2011 | Mar | DISC |
| >A> | @ | 60MG | A 077081 | 007 | Jul 21, 2011 | Mar | DISC |
| >D> | | 180MG | A 077081 | 009 | Jul 21, 2011 | Mar | DISC |
| >A> | @ | 180MG | A 077081 | 009 | Jul 21, 2011 | Mar | DISC |
| >D> | TEVA | 60MG | A 076447 | 007 | Apr 13, 2011 | Mar | DISC |
| >A> | @ | 60MG | A 076447 | 007 | Apr 13, 2011 | Mar | DISC |
| >A> | TIME CAP LABS | 60MG | A 079112 | 003 | Feb 08, 2012 | Mar | CAHN |
| >A> | | 180MG | A 079112 | 005 | Feb 08, 2012 | Mar | CAHN |
| >D> | WOCKHARDT | 60MG | A 079112 | 003 | Feb 08, 2012 | Mar | CAHN |
| >D> | | 180MG | A 079112 | 005 | Feb 08, 2012 | Mar | CAHN |

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

| | | | | | | | |
|-----|---------------------|--------------|----------|-----|--------------|-----|------|
| >A> | GLENMARK PHARMS LTD | 0.05MG/SPRAY | A 218742 | 001 | Mar 16, 2026 | Mar | NEWA |
|-----|---------------------|--------------|----------|-----|--------------|-----|------|

ADDITIONS/DELETIONS FOR OTC DRUG PRODUCT LIST

IBUPROFEN

TABLET;ORAL

IBUPROFEN

| | | | | | | |
|-----|------------------|-------|-------------|--------------|-----|------|
| >D> | AMNEAL PHARMS NY | 200MG | A071333 001 | Feb 17, 1987 | Mar | DISC |
| >A> | @ | 200MG | A071333 001 | Feb 17, 1987 | Mar | DISC |

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

| | | | | | | |
|-----|----------------------|--------|-------------|--------------|-----|------|
| >D> | + HISAMITSU PHARM CO | 3%;10% | N022029 002 | Nov 05, 2012 | Mar | CHRS |
| >A> | + | 3%;10% | N022029 002 | Nov 05, 2012 | Mar | CHRS |

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | |
|-----|-----------------|--------------|-------------|--------------|-----|------|
| >D> | @ PHARMOBEDIANT | EQ 75MG BASE | A075497 001 | Jan 14, 2000 | Mar | CAHN |
| >A> | @ RISING | EQ 75MG BASE | A075497 001 | Jan 14, 2000 | Mar | CAHN |

CURRENT MONTH ADDS/DELETES LIST NOTE:

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>.

The change code description:

| | |
|--------|---|
| NEWA | New drug product approval usually in the supplement month. |
| NFTG | New first time generic approval. |
| CAHN** | Applicant holder firm name has changed. |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |
| CDFR | Change. Dosage Form; Route of Administration. |
| CFTG | Change. A first time generic for the innovator product. A TE Code is added. |
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMKT | Change. RX to OTC marketing status switch. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug. |
| CHRS | Change. Reference Standard. |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition. |

**Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book(EOB)query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.